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ABSTRACT 
More than thirty years after the discovery that Human Immunodeficiency Virus (HIV) was 
the causative agent of Acquired Immunodeficiency Syndrome (AIDS), the disease remains 
pandemic as long as no effective universal vaccine is found. Over 34 million individuals in 
the world are infected with the virus, and the vast majority of them have no access to the 
antiretroviral therapies that have largely reduced HIV to a chronic disease in the developed 
world. The first chapter of this thesis introduces the history of the virus. The key to the 
infectious mechanism of the virus lies in its envelope glycoprotein (Env), a trimeric spike 
on the viral surface that utilizes host T cell receptors for entry. Though HIV-1 Env is 
immunogenic, most infected patients do not mount an effective neutralizing antibody 
response against it. Broadly-neutralizing anti-Env antibodies (bNAbs) present in the serum 
of a minority of infected individuals are usually sufficient to prevent the progression to full 
blown AIDS. Thus, the molecular details of these bNAbs as well as the antibody-antigen 
interface are of prime interest for structural studies, as insight gained would contribute to 
the design of a more effective immunogen and potential vaccine candidate. The second 
chapter of this thesis describes the low-resolution crystal structure of one such antibody, 
2G12 dimer, which targets a high mannose epitope on the surface of Env. Patients infected 
with HIV-2, a related virus with ~35% sequence identity in the Env region, can generally 
mount a robust antibody response sufficient for viral control for reasons still unknown. The 
final two chapters of this thesis focus on the first reported structural studies of HIV-2 Env, 
the molecular details of which may inform HIV-1 therapy and immunogen design.  
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  Chapter 1: Introduction 
 
Discovery of HIV/AIDS 
The first official record of the AIDS epidemic was published in a Morbidity and 
Mortality Weekly Report (MMWR) by the Centers of Disease Control and Prevention 
(CDC) on June 5, 1981(Centers for Disease, 1981). The report described the unusual 
incidence of Pneumocystis carinii pneumonia (PCP) and other secondary infections in 
five previously healthy, young, gay men, two of whom had already died. In the months 
that followed, numerous national newspapers converged on this story. Reports of similar 
opportunistic infections in patients with similar profiles began emerging from hospitals 
across the United States, including many cases of Kaposi’s Sarcoma, a rare but 
aggressive cancer (Altman 1981)(Hymes et al., 1981). By the end of the following year, 
immunodeficiency was determined to be the direct cause of these mysterious infections, 
and the term acquired immunodeficiency syndrome (AIDS) was used for the first time to 
describe the litany of illnesses that plagued a growing population of patients (AIDS.gov).  
In 1983, through the efforts of Drs. Luc Montagnier, Francoise Barre-Sinoussi, 
and Robert Gallo, analysis of viral DNA within human T cells of infected patients 
revealed that AIDS was caused by a retrovirus – namely, a virus that uses reverse 
transcriptase to transcribe viral RNA into DNA before integrating into the host genome 
(Barre-Sinoussi et al., 1983). Human immunodeficiency virus (HIV) was subsequently 
isolated in the lab and characterized as a member of the genus lentivirus, in the family 
retroviridae, meaning that it uses positive sense single-stranded RNA as its genetic 
material and employs a long latency period as a part of its lifecycle. Over the next ten 
1
	  years, the first clinical trials of ziduvidine (AZT) and other antiretroviral therapies (ART) 
targeting reverse transcriptase were conducted in the U.S. with significant but fairly 
unsatisfying results (Fischl et al., 1987). At the 11th International Conference on AIDS in 
1996, a series of new studies presented promising trends from trials of triple-drug 
cocktails, including potent HIV protease inhibitors (Gulick et al., 1997; Hammer et al., 
1997). From that point on, multi-drug therapy using a combination of reverse 
transcriptase and/or protease inhibitors has been the standard of treatment, resulting in a 
60-80% decline in AIDS incidence and death just over the first decade in patients treated 
with highly-active antiretroviral therapy (HAART) (Michaels et al., 1998).  
AIDS has afflicted nearly 75 million people thus far (UNAIDS 2013). As of 2012, 
around 34 million living people were infected with HIV worldwide, up from about 8 
million in 1990 (World Health Organization). Around 70% of this global epidemic is 
made up of patients in sub-Saharan Africa, whose underdeveloped infrastructure and low 
income preclude the use of the most effective ART therapies. For the minority of patients 
who live in in developed countries with access to HAART, HIV infection is now a 
manageable, chronic infection (Palella et al., 1998). A total of 1.7 million AIDS-related 
deaths still occur each year, with 1.2 million in sub-Saharan Africa (World Health 
Organization). There are initiatives underway to improve the sexual education and 
healthcare infrastructures in those countries, but an inexpensive HIV vaccine would be 
the true solution for reducing HIV incidence and AIDS deaths.  
In 1984, after the isolation of HTLV-III (later known as HIV), the CDC 
triumphantly predicted that they hoped “to have a vaccine ready for testing in about two 
years.” (Watkins, 2008). Over 30 years later, the goal of an effective HIV vaccine has 
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  still not been realized. In pursuit of this, however, the scientific community has 
contributed to an enormous body of knowledge surrounding HIV biology, pathogenesis, 
mode of infection, potential therapies, and patient outcomes. To date, many different 
types of HIV vaccines have been tested in volunteers. Trials of live attenuated or 
inactivated HIV vaccines like those used for influenza or poliovirus have been done in 
non-human primates (Daniel et al., 1992). These have been found to be either unsafe or 
risky, as many test subjects still progressed to AIDS (Baba et al., 1995).  
Much work has been done to develop a vaccine based on the individual protein 
components of HIV. Especially extensive strides have been made in the study of the HIV 
envelope spike glycoprotein gp160 (composed of gp120 and gp41), which the virus 
requires to infect human host cells. Efforts to study the details of these protein subunits 
and their interactions with components of the human immune system have been greatly 
aided by the tools of structural biology, including X-ray crystallography and electron 
microscopy. The first co-crystal structure of HxBc2 gp120 in complex with the CD4 
human host receptor and a fragment of 17b, an anti-HIV antibody, was solved in 1998 
(Kwong et al., 1998). This set off the determination of a series of crystal structures of 
various gp120 proteins from different strains of HIV type 1 in the presence of 
neutralizing antibodies. The collective knowledge amassed from those studies has been 
contributing toward a more comprehensive and accurate view of the interface at which 
HIV engages the immune system. The ultimate goal is to rationally design a vaccine, 
scaffold, or therapeutic using detailed molecular insight into what HIV looks like during 
an infection. The studies described in this work were conducted with that goal in mind. 
Presented here are the low-resolution crystal structure of a potent, dimeric form of 2G12, 
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  an antibody against HIV-1 (Chapter 2), as well as the first crystal structure of the 
envelope glycoprotein from HIV-2 in complex with the CD4 host receptor (Chapter 3). 
Additionally, I describe preliminary results from efforts to create a soluble, cleaved, 
native-like HIV-2 envelope glycoprotein trimer (Chapter 4).  
 
Evolutionary history of HIV  
HIV exists in two types, 1 and 2, each of which can be classified into many different 
groups, subtypes, and strains. Both types are thought to have resulted from zoonotic 
transmission events from Simian Immunodeficiency Virus (SIV), which infects non-
human primates. After the first formal documented incidence of HIV-1, the origins were 
traced back to SIV via a case of HIV-2 infection in 1986 (Clavel et al., 1986a). HIV-2, 
unknown at the time, was found to be closely related to a simian lentivirus that infected 
macaques and caused a mild AIDS-like illness, later termed SIV (Chakrabarti et al., 
1987; Clavel et al., 1986b). Most SIVs are nonpathogenic, and chronic infection with an 
SIV is not uncommon in primates, sometimes affecting 50% of an entire species (Sharp 
and Hahn, 2011). It eventually became clear that HIV-1 and HIV-2 emerged from simian 
viruses infecting non-human primates in Africa – chimpanzees (cpz) and sooty mangabey 
monkeys (smm), respectively (Hirsch et al., 1989; Huet et al., 1990). SIV infections have 
only been found in African primates, so it is thought that primate lentiviruses emerged 
after the split of Old World Monkeys into Asia and Africa. Non-human primate cross-
species transfers of SIV have been known to occur, but it is uncertain what role this may 
have played in the emergence of HIV (Hahn et al., 2000; Sharp et al., 2000). 
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  A study conducted between 2000-2009 in Gombe National Park, Tanzania 
revealed that SIVcpz spreads sexually and leads to a 10- to 16- fold increased risk of death 
in infected chimpanzees (Pan troglodytes troglodytes) after an AIDS-like illness 
featuring progressive CD4+ T cell depletion (Santiago et al., 2002). HIV-1 Group M, the 
type responsible for the global AIDS epidemic, is most closely related to SIVcpz found in 
these animals (Lemey et al., 2004). It has been hypothesized that human encounters with 
apes in the early 1900s via injuries incurred during bush meat hunting were the cause of 
zoonotic transfers of SIV (Korber et al., 2000; Lemey et al., 2004). HIV-2 was proposed 
to have descended from SIVsmm in sooty mangabeys, which is nonpathogenic but 
widespread in its natural host organism (Gao et al., 1992). HIV-2 Groups A and B are 
most commonly found in humans, and generally cause a much milder illness than HIV-1 
Group M does (Popper et al., 2000). For unknown reasons, patients infected with HIV-2 
often sustain appreciable CD4+ T cell counts and mount a robust immune response with 
broadly neutralizing antibodies (Berry et al., 2002). The last two chapters of this work 
represent the first structural studies of the HIV-2 envelope glycoprotein in an effort to 
investigate the reasons for the differences in pathogenicity between the two types of HIV.  
From recent viral archaeology studies, the AIDS pandemic is thought to have 
originated from HIV-1 group M infections in Kinshasa (formerly Leopoldville), Republic 
of Congo around the early 1920s (Faria et al., 2014; Sharp and Hahn, 2011). An 
increasingly trafficked railway network in Kinshasa combined with a robust sex trade 
facilitated the rapid explosion of HIV to surrounding urban centers in the 1960s. The 
virus then mutated rapidly via its error-prone reverse transcriptase and short generation 
times as it spread farther, leading to diversification into geographically distinct subtypes 
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  over a short period of time. Through various genetic bottlenecks, epidemics broke out in 
different regions of the world: notably subtype C in Africa and subtypes A and B in 
Europe and the Americas (Faria et al., 2014). Subtype B is thought to have spread to 
Haiti from Africa in the 1960s, then spread to the United States via a single migration 
event at the end of the decade (Worobey et al., 2008). These results suggest that HIV was 
circulating in the United States well before the first officially documented cases. The 
traits of the virus that enabled its rapid spread throughout the globe are the very ones that 
help it to successfully evade the human immune system.  
 
The role of Env in HIV infection 
HIV is an enveloped virus, which means that it utilizes a mainly host-derived 
membrane enclosing a protein capsid containing genetic material, all of which it 
synthesizes and assembles using host machinery. The key to infecting host cells lies in 
the envelope glycoprotein (Env), which is a trimer of heterodimeric proteins embedded in 
the envelope. The virus uses this protein to recognize and bind to a host cell via host 
receptors, and it subsequently fuses to the host cell via choreographed steps (Marsh and 
Helenius, 2006). Enveloped viruses generally enter host cells by directly fusing to the 
plasma membrane, or via pH dependent endocytosis, leading to fusion within an 
endosome (Blumenthal et al., 2012). HIV is able to infect cells at neutral pH by directly 
fusing to the plasma membrane, but there has been some evidence that it can fuse via 
endosomes as well (Wilen et al., 2012).  
The envelope glycoprotein gp160 is expressed in the endoplasmic reticulum and 
trafficked to the Golgi, where it undergoes post-translational cleavage into the 
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  noncovalently associated gp120 and gp41 subunits by the protease furin (Checkley et al., 
2011). These subunits are then incorporated into the plasma membrane as a trimer of 
heterodimers (gp120-gp41). Gp120 contains five constant domains (C1-C5), which are 
highly conserved and concealed in a core structure, and five variable loops (V1-V5), 
which are well exposed on the surface of gp120 and undergo rapid mutation to evade the 
immune system. Further, gp120 can be roughly divided into inner and outer (with respect 
to the N- and C-termini) domains, and a set of four β-strands bridging the gap between 
the two, dubbed the “bridging sheet”. 
HIV initially approaches the host membrane via electrostatic forces or nonspecific 
attachment to host membrane elements, allowing the envelope spike to access and bind to 
the CD4 host receptor on the surface of T cells (Pantophlet and Burton, 2006) using a 
conserved CD4 binding site (CD4bs, (Kwong et al., 1998)). CD4 is normally responsible 
for mediating T cell receptor signaling, a critical component of host physiology that the 
virus exploits for its own infection mechanism. CD4 binding results in a conformational 
change in gp120, inducing shifts in the variable loops V1/V2 and V3 as well as the 
bridging sheet and inner domain elements to expose key elements for subsequent 
coreceptor binding. Binding also induces a hinging of the CD4 domains, which may 
bring the virus closer to the membrane as well as structural rearrangements in regions of 
gp41, which prepare the envelope spike for fusion (Blumenthal et al., 2012). HIV strains 
can be distinguished by their chemokine receptor usage, with the majority binding to the 
G-protein coupled receptors CCR5 (termed R5 viruses) or CXCR4 (termed X4 viruses) to 
trigger subsequent fusion. Some laboratory adapted strains of HIV-1 can trigger cell entry 
with only coreceptor binding in the absence of CD4, suggesting that singular coreceptor 
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  usage may have been an archaic fusion mechanism for HIV (Borsetti et al., 2000). After 
coreceptor binding, the virus positions itself for viral fusion along the plasma membrane 
(Marsh and Helenius, 2006). There is also some evidence that HIV gets endocytosed at 
the plasma membrane and fuses with endosomes in a dynamin-dependent fashion 
(Miyauchi et al., 2009). 
The gp41 fusion peptide is exposed by conformational changes during coreceptor 
binding, and inserts into the host cell membrane. The gp41 trimer then forms a six-helix 
bundle (Chan et al., 1997) and brings the viral and host membranes into close proximity 
to form a stabilized fusion pore (Melikyan, 2008). Gp120 is then likely disengaged from 
the gp41 stalk to allow for refolding of the fusogenic coiled coil. To complete pore 
formation, the trimeric gp41 six-helix bundle forms upon refolding and brings its two 
membrane-anchored regions into range in a hairpin-like fashion (Melikyan, 2008).   
 
Broadly neutralizing antibodies against HIV 
Env is the sole known antigenic target of neutralizing antibodies against HIV (Pantophlet 
and Burton, 2006). Patients infected with HIV-1 produce many antibodies against Env, 
but few of them are effective enough to neutralize across several strains. As a result, most 
patients progress to full blown AIDS. In contrast, HIV-2 Env is highly immunogenic and 
elicits much more effective and broad antibodies in patients (Kong et al., 2012a; Kong et 
al., 2012b). HIV-2 patients retain high CD4+ T cell counts and exhibit low 
transmissibility of the virus (see Chapter 3) (Kong et al., 2012a; Kong et al., 2012b).  
The causes of an ineffective neutralizing antibody response against HIV-1 are 
several fold: conformational masking (Kwong et al., 2002) and steric occlusion of 
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  conserved epitopes (Labrijn et al., 2003), glycan shielding and rapid mutation of variable 
regions to produce variants resistant to therapy (Wei et al., 2003), and sparse distribution 
of envelope spikes (Klein and Bjorkman, 2010).  Vaccines that have been developed 
against other enveloped viruses such as influenza and poliovirus are sufficient to elicit 
neutralizing antibodies to control infection (Kwong and Wilson, 2009). While the 
envelope spike protein of many of these viruses also exhibit traits that make it difficult to 
make antibodies against HIV, a key difference lies in the sparse distribution of spikes on 
HIV compared to relatively abundant spikes on the other viruses (Klein and Bjorkman, 
2010). Therefore, antibodies against other viruses can exploit avidity effects via inter-
spike crosslinking, i.e., bivalent binding to adjacent spikes using both antibody arms. 
Antibodies against HIV are unable to accomplish this without intervention (Galimidi et 
al., 2015) due to there being only ~14 spikes on the surface of the virus (Klein and 
Bjorkman, 2010; Zhu et al., 2003). Despite this, up to 25% of infected individuals, called 
long-term nonprogressors, are able to make neutralizing antibodies against HIV-1 Env 
(Doria-Rose et al., 2009; Montefiori et al., 1996) and do not progress to full blown AIDS 
(Migueles et al., 2000).  
The first structure of HIV-1 gp120, from the strain HxBc2, was in complex with 
an antigen binding fragment (Fab) of the CD4-induced antibody 17b as well as two 
domains of the CD4 receptor (Kwong et al., 1998). Since then, especially after the 
development of single-cell antibody cloning (Scheid et al., 2009), more than dozens of 
antibody Fab structures have been solved in complex with gp120. The molecular details 
of their epitopes have been systematically elucidated, and these include the CD4-binding 
site, nonspecific high mannose glycans, the Asn332 N-linked glycosylation site and 
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  associated V3 loop, the Asn160 N-linked glycosylation site and associated V1/V2 loops,  
and the membrane proximal region (MPER) (West et al., 2014).  
In 2013, X-ray crystallographic and cryo-electron microscopy structures of a 
soluble, cleaved form of the Env trimer were solved at 4.7 Å and 5.8 Å, respectively 
(Julien et al., 2013; Lyumkis et al., 2013). Key to this remarkable advance was a 
recombinant gp140 protein from the BG505 strain, dubbed “SOSIP”, featuring a trimer-
stabilizing mutation within gp41 and covalent linkage of the gp120 and gp41 subunits via 
a disulfide bond (Sanders et al., 2013). This long-pursued target revealed important 
quaternary interfaces of the HIV-1 trimer that could not be appreciated via crystal 
structures of monomeric gp120. Epitope mapping using EM reconstructions of antibody 
Fabs bound to the trimer have revealed several epitopes that were previously 
incompletely defined in the context of gp120 monomers (Derking et al., 2015). Chapter 4 
of this work describes preliminary data resulting from initial attempts to create a HIV-2 
version of the SOSIP trimer.  
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ABSTRACT 
2G12 is a human IgG that recognizes high-mannose carbohydrates on the HIV-1 
envelope protein gp120. Its two antigen-binding fragments (Fabs) are intramolecularly 
domain exchanged, resulting in a rigid (Fab)2 unit including a third antigen-binding 
interface not found in antibodies with flexible Fab arms. We determined crystal structures 
of dimeric 2G12 IgG created by intermolecular domain exchange, which exhibits 
increased breadth and 50- to 80-fold increased neutralization potency compared with 
monomeric 2G12. The four Fab and two Fc regions of dimeric 2G12 were localized at 
low resolution in two independent structures, revealing IgG dimers with two (Fab)2 arms 
analogous to the Fab arms of conventional monomeric IgGs. Structures revealed three 
conformationally-distinct 2G12 dimers, demonstrating flexibility of the (Fab)2–Fc 
connections that was confirmed by single particle electron microscopy, small angle X-ray 
scattering, and binding studies. We conclude that a combination of intermolecular 
domain exchange, flexibility, and bivalent binding to allow avidity effects is responsible 
for the high neutralization potency and increased breadth of dimeric 2G12. 
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INTRODUCTION 
Difficulties in generating broadly neutralizing antibodies against human 
immunodeficiency virus type 1 (HIV-1) lie in structural features of the gp120-gp41 
envelope spike trimer: the spike’s variable loops are highly susceptible to rapid mutation 
(Starcich et al., 1986), its few conserved regions are often sterically occluded via 
conformational masking (Kwong et al., 2002), and a host-derived glycan shield covers 
much of the spike surface, making gp120 one of the most heavily glycosylated proteins in 
nature (Poignard et al., 2001). As such, surface carbohydrates contribute to roughly 50% 
of gp120’s molecular weight (Botos and Wlodawer, 2005). Despite the fact that most 
antibodies elicited against HIV-1 are strain-specific, there exists a small set of broadly 
neutralizing antibodies that have demonstrated efficacy across strains (Kwong and 
Mascola, 2012; Mascola and Haynes, 2013). Isolated from the blood of infected 
individuals, these antibodies have been found to target conserved epitopes on either the 
gp120 or gp41 subunits of the envelope spike protein.  
Human monoclonal antibody 2G12 recognizes clusters of N-linked high-mannose 
(Man8-9GlcNAc2) glycans on the surface of gp120 (Calarese et al., 2005; Sanders et al., 
2002; Scanlan et al., 2002) and effectively neutralizes many Clade B and some Clade A 
strains of HIV-1 (Trkola et al., 1996). 2G12’s ability to target glycan clusters is 
facilitated by three-dimensional domain swapping (Liu and Eisenberg, 2002) of its heavy 
chains to form a rigid (Fab)2 antigen-binding unit (Calarese et al., 2003). By contrast, two 
independent antigen-binding units are found in conventional IgGs, which contain two 
heavy chains and two light chains arranged into two fragment antigen-binding (Fab) 
regions and a single fragment crystalline (Fc) region (Figure 1A). In a typical Fab, the 
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two domains of the light chain (the variable light (VL) and constant light (CL) domains) 
pair with the variable heavy (VH) and constant heavy 1 (CH1) domains, respectively, of a 
single heavy chain. In the domain-swapped (Fab)2 unit of monomeric 2G12, each light 
chain is associated with both heavy chains, such that the CL domain of a light chain 
contacts CH1 from one heavy chain, and the VL domain from that light chain contacts the 
VH domain from the second heavy chain (Calarese et al., 2003). The result is a single 
rigid (Fab)2 unit that contains a third antigen binding site at the VH/VH’ interface in 
addition to the two primary antigen binding sites formed by the VH/VL interfaces (Figure 
1B). The unique VH/VH’ site allows for increased glycan contacts at the binding surface 
of 2G12, allowing it to target densely clustered carbohydrates that might be inaccessible 
to conventional IgG antibodies (Calarese et al., 2003).  
During the purification of recombinant 2G12, we previously found that 2G12 
formed monomers (two Fabs and one Fc) plus a small fraction of a higher molecular 
weight species, which was 50- to 80-fold more potent than 2G12 monomer in 
neutralization of clade A and B HIV-1 (West et al., 2009). This species, identified as 
2G12 dimer (four Fabs, two Fcs), was proposed to form through intermolecular domain 
swapping rather than the intramolecular domain swapping that results in 2G12 monomer 
(Figure 1C; Figure S1A). Both monomer and dimer were produced during expression in 
mammalian cells and could be separated by size-exclusion chromatography into purified 
samples that did not interconvert upon storage or concentration. 
Because 2G12 dimer is extremely potent and some 2G12 monomer-resistant HIV 
strains were neutralized by dimer, increasing the proportion of 2G12 dimer could lead to 
a more effective reagent for gene therapy or passive immunization. Indeed, introduction 
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of a higher dimer/monomer ratio 2G12 cell line (West et al., 2009) into HIV-1-infected 
humanized mice increased protection against infection compared with the wild-type 
2G12-expressing cell line, and injection of 2G12 dimer, but not monomer, controlled 
HIV-1 infection in mouse models (Luo et al., 2010). In addition to its increased capacity 
for antigen recognition, 2G12 dimer also has the potential for protection via effector 
functions because it can mediate antibody-dependent cellular cytotoxicity (ADCC) in 
vitro (Klein et al., 2010), indicating that it retains binding to the CD16 Fc receptor on 
natural killer cells despite its unusual structure.  
To investigate the structural and mechanistic basis of the increased potency of 
2G12 dimer compared with the monomer, we solved two independent, low-resolution 
structures of 2G12 dimer by X-ray crystallography. Our efforts were aided by high 
resolution structures of the 2G12 (Fab)2 (Calarese et al., 2003) and an IgG Fc (Krapp et 
al., 2003). We performed several structural validations to confirm the 2G12 dimer 
structures. Collectively the structures revealed three conformationally-distinct forms of 
the dimer, suggesting that the two (Fab)2 units can adopt different positions relative to the 
Fcs, analogous to the flexibility of the two Fab arms of a conventional IgG. Consistent 
with the crystal structures, single particle electron microscopy and small-angle X-ray 
scattering studies confirmed the flexible nature of 2G12 dimer. Additionally, we showed 
that 2G12 dimer, but not 2G12 monomer, could bind bivalently to immobilized gp120 in 
a biosensor assay and confirmed that both Fc regions in the 2G12 dimer were accessible 
to an Fc receptor using binding and stoichiometry measurements. Our results provide a 
structural explanation for the superior neutralization potency of 2G12 dimer compared 
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with monomer (West et al., 2009) and rationalize the dimer’s ability to mediate Fc-
mediated effector functions (Klein et al., 2010).  
 
RESULTS 
Crystallization and structure determination of 2G12 dimer  
Structure determinations of intact antibodies are inherently limited by flexibility between 
domains, and in the case of 2G12, the existence of multiple oligomeric states. Despite 
these challenges, we were able to readily obtain crystals of intact purified 2G12 dimer. 
The best crystals (space group P6122) diffracted to only 7.4 Å (Table S1) despite 
optimizing crystallization conditions and screening >500 crystals. We obtained 
preliminary phases using molecular replacement with the 2G12 (Fab)2 (pdb entry 1OP3) 
and IgG Fc (pdb entry 1H3X) structures as search models and verified the solution using 
heavy atom derivative data (Figure 2; Figure S2, Table S1). Three 2G12 (Fab)2 units 
were initially located in the crystallographic asymmetric unit (Figure 2A). The Fc regions 
were found only in molecular replacement searches involving a fixed partial solution 
including the (Fab)2 units. Crystallographic R values after rigid body and B-factor domain 
refinement decreased from 0.50 to 0.37 after placing the Fc regions. The final model at 
8.0 Å resolution (Rwork = 0.35; Rfree = 0.37) (Table S1) contained three (Fab)2 units and 
three Fc regions representing three separate half-dimers (Figure 2A). Applying 
crystallographic two-fold symmetry operations generated three physiological 2G12 
dimers, each with two (Fab)2 units and two Fc regions (Figure 2B). The (Fab)2 units of 
the 2G12 dimers contacted each other at their antigen binding sites (Figure 2A). They 
were flanked by pairs of Fc regions that formed a hexamer via a six-fold non-
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crystallographic symmetry (NCS) axis coincident with a crystallographic 61 screw axis 
(Figure 2C). The Fc regions forming the hexamers contacted each other at the hinge 
between the CH2 and CH3 domains, the so-called “hot spot” on IgG Fc for interactions 
with receptors and other proteins (DeLano et al., 2000). 
 The placement of the (Fab)2 and Fc regions in the P6122 unit cell was dependent 
upon NCS relating the three half-dimers in the crystallographic asymmetric unit, which 
we sought to validate to confirm model accuracy. A self-rotation function yielded no 
peaks for NCS (data not shown). However, NCS axes that are parallel to crystallographic 
axes of the same or higher symmetry are not detected in self-rotation functions because 
their peaks coincide with peaks corresponding to crystallographic axes (Rupp, 2010). An 
NCS axis parallel to a crystallographic can be detected as a peak in a native Patterson 
map (Rupp, 2010). A native Patterson calculated using the 8 Å P6122 data showed peaks 
at positions 1/6, 1/3, and 1/2 along the w axis (Figure 3A,B). These peaks resulted from 
the six-fold rotational NCS axis formed by the hexamer of Fc regions along (and parallel 
to) the crystallographic 61 screw axis (Figure 3C). Structure factors calculated from the 
model of 2G12 half-dimers in the P6122 asymmetric unit reproduced these peaks in a 
native Patterson calculation (Figure 3A,B), validating the placement of the (Fab)2 and Fc 
regions in the low-resolution 2G12 dimer structure. 
 
Overall structure of 2G12 dimer 
Two of the 2G12 dimers (dimers B and C) in the P6122 crystals were conformationally 
identical, whereas the third dimer (dimer A) was distinct (Figure 4A,B; Figure S4A,B). 
The (Fab)2 arms of dimers B and C were related by an angle of ~ 100˚, similar to a typical 
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angle between a pair of Fab arms in a conventional, non-domain-swapped IgG antibody 
(Roux, 1999), and the (Fab)2 arms of dimer A were related by ~ 180° (Figure 4A,B). The 
difference in relative positions of the (Fab)2 arms is consistent with flexibility between 
the two (Fab)2 portions of the 2G12 dimer structure, in contrast to the inflexibility of the 
single rigid (Fab)2 of 2G12 monomer. The span between the combining sites of the two 
(Fab)2 arms of 2G12 dimers, ranging from 105 to 170 Å, was similar to the combining 
sites of the two Fab arms of a conventional IgG, which are separated by ~ 150 Å (Klein 
and Bjorkman, 2010). These findings suggest that 2G12 dimer exhibits enhanced 
neutralization potency due to its ability to bind HIV spikes bivalently with flexible (Fab)2 
arms, as compared with 2G12 monomer, which binds monovalently using a single (Fab)2 
arm.  
Our data also support a novel mechanism for creating IgG dimers via 3-D domain 
swapping. In this model, each Fc is a hybrid, with each chain derived from a different 
monomer (Figure S1A). The heavy chain portions of each (Fab)2 unit in the 2G12 dimer 
each pair with the CH2-CH3 region (i.e., the Fc) extending from a neighboring (Fab)2 to 
form a hybrid Fc. As in other intact IgG structures (Guddat et al., 1993; Harris et al., 
1997; Harris et al., 1998; Kratzin et al., 1989; Saphire et al., 2001), the hinge regions of 
the 2G12 dimers were not resolved in the electron density maps. However, the orientation 
of the Fc regions in the three 2G12 dimers supported the connectivity model. The model 
was also consistent with the propensity of 2G12 to form higher order oligomers, 
including trimers (Figure S1B), which were evident in size-exclusion chromatography 
profiles of 2G12 (Figure S1C).  
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Crystallization and structure determination of 2G12 dimer/2G12.1 peptide complex 
Packing in the P6122 2G12 dimer crystals involved contacts between the antigen binding 
sites of adjacent (Fab)2 units (Figure 2A). We reasoned that disrupting these contacts 
could allow 2G12 dimer to crystallize in a different packing arrangement that might 
diffract to higher resolution. To disrupt the contacts, we crystallized 2G12 dimer in the 
presence of 2G12.1, a 21-residue synthetic inhibitor peptide that binds to the combining 
site of 2G12 (Fab)2 with an affinity of ~200 µM (Menendez et al., 2008). Clustered 
hexagonal crystals of 2G12 dimer formed in crystallization trials involving a 19:1 
peptide-to-protein molar ratio. By isolating regions of singularity from the clusters, we 
were able to collect a 6.0 Å data set in space group P6 from a single crystal. We solved 
the 2G12 dimer/2G12.1 peptide complex structure to 6.5 Å using molecular replacement 
as described for the 2G12 dimer structure (Table S1). The angle between the (Fab)2 units 
and Fcs in the 2G12 dimer in this crystal form (Figure 4C) was different from either 
dimer A or dimer B in the P6122 2G12 dimer crystals (Figure 4A,B), and thus molecular 
replacement worked only when we used separate (Fab)2 and Fc search models, resulting 
in an R-value decrease from 0.45 to 0.40 after the Fc region was correctly introduced into 
the model. Although low resolution precluded visualization of the 2G12.1 peptide in the 
antigen binding site, introduction of the peptide altered the packing such that there were 
no crystal contacts involving the (Fab)2 antigen binding site (Figure S3A). However, the 
Fc regions of 2G12 dimer were arranged as hexamers in the 2G12/2G12.1 crystals 
(Figure S3B), as also found in the packing of the 2G12 dimer crystals (Figure 2C; Figure 
3C).  
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It was initially difficult to determine the connectivity between the (Fab)2 and Fc 
regions of the 2G12 dimer in the 2G12/2G12.1 structure because the Fc regions were 
arranged almost parallel to the (Fab)2 units (Figure 4C). The (Fab)2–Fc connections in the 
2G12 dimer/2G12.1 complex structure were interpreted by assigning probable 
connectivity between the N-termini of the four heavy chains of the two Fc regions and 
the C-termini of the four heavy chains of the two (Fab)2 units. Taken together, 19 
residues within the 2G12 hinge region were missing from the (Fab)2 and Fc structures 
used as search models for molecular replacement. Distances from the N-termini of the 
four Fc polypeptide chains to the C-termini of the four (Fab)2 heavy chains were 
measured using coordinates for high resolution models placed into the 2G12 
dimer/2G12.1 structure for residues Pro-238 (N-terminus of Fc) and Lys-228 (C-terminus 
of the (Fab)2 heavy chain) (residue numbering based on the structures of 2G12 (Fab)2 
(pdb ID 1OP3) and Fc (pdb ID 1H3X). Using the shortest combinations of distances as 
the most plausible choice for connectivity between the chains, we derived the same 
hybrid Fc model of intermolecular domain exchange as deduced for the formation of the 
2G12 IgG dimer (Figure S1A). Assuming this connectivity, the 2G12 dimer in the 
2G12/2G12.1 crystal structure adopted a conformation distinct from the two found in the 
2G12 dimer alone structure: the Fc regions were oriented at 180° with respect to each 
other and were essentially parallel to the (Fab)2 units, which were also splayed ~180° 
apart (Figure 4C), similar to dimer A from the P6122 structure (Figure 4A). Comparison 
of the three 2G12 dimer conformations obtained from the 2G12 dimer and 2G12 
dimer/2G12.1 complex structures demonstrated a large range of conformations accessible 
to the 2G12 dimer (Figure 4; Figure S4).   
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Electron microscopy (EM) studies of 2G12 dimer and higher-order oligomers 
Negative stain EM and reference-free 2D classification is a powerful method for 
generating observations of single particles. Here we studied the different fractions eluted 
from an SEC purification (Figure S1C) that corresponded in apparent molecular weights 
to 2G12 monomer, dimer, and trimer. Reference-free 2D classes for each of the 2G12 
species, including isolated 2G12 (Fab)2, were calculated (Figure 5). In many of the 
classes for 2G12 dimer and higher-order oligomers, the 2G12 (Fab)2 was discernable and 
the Fc less clear. The classes corresponding to the dimer and trimer were consistent with 
an intermolecular domain-swapping model as deduced from the crystal structures. The 
lack of well-defined class averages for 2G12 IgGs in comparison to a 2G12 (Fab)2 alone 
(Figure 5A) suggested that 2G12 IgG monomers, dimers, and trimers are flexible 
structures (Figure 5B-D). In the case of 2G12 monomer, the flexibility presumably 
resulted solely from the connection between the Fc and the rigid (Fab)2 unit, whereas the 
2G12 multimers could adopt different positions of their (Fab)2 units with respect to their 
Fc regions and each other. Attempts to generate 3-D reconstructions of these particles 
produced maps that were difficult to interpret, also indicative of conformational 
heterogeneity. To assess the similarity of the 2G12 IgG dimer models analyzed via 
crystallography and negative stain EM, the crystal structure of dimer A (Figure 2B; 
Figure 3A) was filtered to 25 Å and back projected at a 20° Euler angle sampling (Figure 
5E). The back projections of 2G12 dimer A showing different orientations of the two 
(Fab)2 pairs with respect to the Fcs consistently matched the independently generated EM 
class averages of the 2G12 dimer.  Small-angle X-ray scattering (SAXS) data collected 
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on the 2G12 IgG dimer were also consistent with the dimensions and flexibility observed 
by EM (Figure 5; Figure S5). 
 
Biosensor assays demonstrate bivalent binding by 2G12 dimer 
The crystal structures, single particle EM images, and SAXS analyses of 2G12 dimer 
suggested that the (Fab)2 units of the IgG dimer are flexible with respect to the Fc region, 
analogous to the two Fab arms of a conventional IgG antibody. If so, then like a 
conventional IgG, 2G12 dimer should be capable of bivalent binding to a tethered 
antigen. By contrast, the intramolecular domain exchange in 2G12 monomer results in a 
rigid structure that does not have two independently movable Fab arms for bivalent 
binding  (Figure 1B). Rather, the (Fab)2 unit behaves as a single unit using its 
conventional combining sites at the VH/VL interfaces plus the site created by the domain-
swapped VH/VH’ region to bind to clusters of glycans (Calarese et al., 2003) and should 
therefore exhibit apparently monovalent binding.  
To verify these predictions, we compared the binding of 2G12 dimer, 2G12 
monomer, and conventional anti-gp120 IgGs to a clade B gp120 using a surface plasmon 
resonance (SPR) binding assay. 2G12 monomer, 2G12 dimer, or monomeric anti-gp120 
IgGs (NIH45-46G54W and 2909) (Diskin et al., 2011; Gorny et al., 2005) were injected 
over a gp120 protein from the clade B SF162 strain that was immobilized on the surface 
of a biosensor chip. The gp120 protein was coupled at high and medium coupling 
densities to permit bivalent binding and at a low density to reveal the potential loss of 
bivalent binding when the (Fab)2 arms of 2G12 dimer or the Fab arms of the conventional 
anti-HIV-1 IgGs could not cross-link between two gp120 molecules. To distinguish 
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between monovalent and bivalent binding, we fit the sensorgram data to a 1:1 binding 
model and assessed the residuals for the goodness of fit (Figure 6; Figure S6). We found 
that 2G12 monomer exhibited apparently monovalent binding to gp120 at all coupling 
densities (Figure 6A-C). As predicted, 2G12 dimer exhibited apparently bivalent binding 
to gp120 at high and medium coupling densities (Figure 6A,B), but monovalent binding 
at low coupling density (Figure 6C). Conventional anti-gp120 IgGs bound with apparent 
bivalency at high coupling density but monovalently at medium and low densities, 
suggesting a smaller reach between combining sites than 2G12 dimer (Figure 6A-C).  
 
The Fc regions of 2G12 dimer are accessible to Fc receptor binding 
The 2G12 dimer structures suggested that the dimer’s Fc regions would be accessible to 
Fc receptor binding, consistent with a study demonstrating that 2G12 dimer triggered 
ADCC (Klein et al., 2010). This effector function is mediated by CD16, an Fc receptor 
that interacts with the hinge-proximal region of the Fc CH2 domain (Sondermann et al., 
2000). The CH2-CH3 domain interface, the binding site for the neonatal Fc receptor 
(FcRn) (Burmeister et al., 1994) and the site of contacts that form the NCS 6-fold axis 
(Figure 2C; Figure 3C; Figure S3B), was also predicted to be accessible for binding. Two 
FcRn proteins bind to the Fc region of a conventional IgG monomer, one per polypeptide 
chain in the Fc (Huber et al., 1993; Sanchez et al., 1999). Since 2G12 dimer contains two 
Fc regions with four potential FcRn binding sites, up to four FcRn proteins could bind per 
2G12 dimer. 
 To characterize the binding interaction between FcRn and 2G12 dimer, we used 
equilibrium gel filtration, a technique that can be used to determine the stoichiometry of a 
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complex that might dissociate during conventional gel filtration chromatography 
(Hummel and Dreyer, 1962). This method was previously used to demonstrate that two 
FcRn molecules bind per IgG monomer (Sanchez et al., 1999; West and Bjorkman, 
2000). For the 2G12 experiments, a gel filtration column was equilibrated with a buffer 
containing 5 µM FcRn, a concentration ~10-fold higher than the KD of the interaction 
between FcRn and IgG in solution (Huber et al., 1993). We then injected various ratios of 
FcRn to 2G12 monomer or dimer.  
 Figure 7 shows gel filtration profiles for 2G12 monomer and 2G12 dimer 
interacting with FcRn. In both chromatograms, the first peak corresponded to the 2G12 
complex with FcRn, which migrated at an apparently higher molecular mass for the 
dimer complex than for the monomer complex. Both chromatograms also showed a peak 
or a trough at the position where unbound FcRn migrated: a peak in the case of the 3:1 
ratio of FcRn per Fc region in 2G12 monomer and the 6:2 ratio of FcRn per Fc region in 
2G12 dimer (indicating excess FcRn) and troughs in the cases of lower ratios of FcRn per 
Fc. Since excess FcRn was present when a 3:1 (or 6:2) ratio of FcRn per Fc was injected, 
the stoichiometry for both complexes is two FcRn proteins bound per Fc region. Thus 
two FcRn molecules were bound per 2G12 monomer, which contains one Fc region, and 
four FcRn molecules were bound per 2G12 dimer, which contains two Fc regions.  
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DISCUSSION 
Among known broadly neutralizing anti-HIV-1 antibodies, 2G12 is unusual in two 
respects: first, it recognizes a carbohydrate epitope on gp120 (Botos and Wlodawer, 
2005), and second, its Fab arms are domain swapped to form a rigid single (Fab)2 unit 
(Calarese et al., 2003). The (Fab)2 unit in monomeric 2G12 is formed by intramolecular 
domain swapping involving the two IgG heavy chains. We hypothesized that 
intermolecular domain swapping could create a dimeric species of 2G12 IgG that was 
observed by size-exclusion chromatography (West et al., 2009). 2G12 dimers can be 
isolated as a stable species that contains two Fc regions and four Fabs arranged into two 
(Fab)2 units. Compared with 2G12 monomer, purified 2G12 dimer is 50- to 80-fold more 
potent in in vitro neutralization assays (West et al., 2009), more effective in protection 
from HIV infection in in vivo experiments (Luo et al., 2010), and mediates ADCC at 
lower concentrations (Klein et al., 2010). The present structural studies were initiated to 
investigate the structural mechanism for the increased activity of 2G12 dimer versus 
monomer.  
Although crystal structures of intact IgGs are rare, with few examples in the 
literature (Guddat et al., 1993; Harris et al., 1997; Harris et al., 1998; Kratzin et al., 1989; 
Saphire et al., 2001), intact 2G12 IgG dimer formed crystals, both alone and complexed 
with the 2G12.1 inhibitor peptide. Both crystal forms diffracted weakly to low resolution, 
but we were able to solve crystal structures by molecular replacement for 2G12 dimer 
and the 2G12 dimer/2G12.1 complex at resolutions between 6.5 and 8 Å. The molecular 
replacement solutions were verified by heavy atom methods and native Patterson 
calculations. The model for connectivity to produce an intermolecular domain-swapped 
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IgG dimer was consistent with the orientation of the Fc domains in both the 2G12 and 
2G12/2G12.1 structures.  
The low resolution structures revealed three distinct conformations of 2G12 dimer. In 
each conformation, the two (Fab)2 units in the dimer were arranged as arms at an obtuse 
angle, analogous to the Fab arms of a conventional IgG monomer that can bind bivalently 
to tethered antigens. The two Fc regions were separated from each other, suggesting they 
would not block each other’s interactions with Fc receptors. Indeed, 2G12 dimer 
interacted with FcRn with proportional stoichiometry as 2G12 monomer in equilibrium 
gel filtration studies, corroborating the idea that Fc regions in 2G12 dimer are as 
accessible for effector functions as the Fc regions in conventional IgGs. 2D class 
averages from negative stain electron microscopy provided unbiased, reference-free 
profiles that visually confirmed the flexibility and orientations of the 2G12 dimers 
observed in crystal structures. The presence of three distinct conformations of 2G12 
dimer indicated that different conformational intermediates were trapped in the two 
crystal forms. Consistent with this suggestion, 2G12 dimer could bind bivalently to 
immobilized gp120, allowing avidity effects to increase the apparent affinity of 2G12 
dimer for its carbohydrate epitope. By contrast, the single rigid (Fab)2 unit of monomeric 
2G12 bound monovalently to immobilized gp120, regardless of the density of the gp120 
on the surface.  
These results are relevant to a hypothesis that a general inability of many anti-
HIV-1 antibodies to bind with avidity is one reason that the antibody response against 
HIV is generally ineffective (Klein and Bjorkman, 2010). Briefly, we proposed that most 
anti-Env antibodies do not bind bivalently to HIV spike trimers because (i) the small 
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number and low density of HIV spike trimers does not normally permit inter-spike 
crosslinking, and (ii) the distance between the same epitope on individual monomers 
within a spike trimer usually exceeds the armspan of a conventional IgG, thereby 
preventing most instances of intra-spike crosslinking. To assess potential bivalent binding 
by anti-viral IgGs, we defined the molar neutralization ratio (MNR) as the concentration 
at which an Fab achieves 50% inhibition of viral infectivity (IC50) divided by the IC50 for 
the parental IgG in an in vitro neutralization assay (Klein and Bjorkman, 2010). An 
antibody that is unable to bind with avidity would exhibit an MNR of 2, because the IgG 
has twice the amount of antigen-binding capacity as the Fab. MNRs greater than 2 
suggest avidity effects resulting from the IgG cross-linking epitopes on the virus. Results 
from published studies showed high MNRs for antibodies against respiratory syncytial 
virus and influenza (Edwards and Dimmock, 2001; Schofield et al., 1997; Wu et al., 
2005), suggesting that antibodies can take advantage of avidity effects to bind to 
enveloped viruses other than HIV-1. However, a compilation of the highest reported 
MNRs for antibodies against HIV showed that neutralizing antibodies yielded relatively 
low MNRs (Klein and Bjorkman, 2010). 
 Although the (Fab)2 unit of monomeric 2G12 interacts with at least three high-
mannose glycans, the binding surface is a single unit, and thus the 2G12 monomer does 
not have the capacity to bind antigen with avidity as it is conventionally defined. 
However, 2G12 dimer can be up to 2500-fold more potent in neutralization than 
monomeric 2G12 on a molar basis (West et al., 2009); thus, the high MNRs for 2G12 
dimer compared to its monomeric form are similar to the large effects seen for 
conventional IgGs against non-HIV viruses (Klein and Bjorkman, 2010). The discovery 
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that 2G12 dimer is a flexible molecule that behaves like an oversized version of a 
conventional IgG antibody now allows us to postulate that avidity effects, rather than 
simply doubling the surface area of a single combining site, account for the mechanism 
by which 2G12 dimer achieves its greater potency compared with 2G12 monomer.  
The 2G12 dimer structure, taken together with what is known about the 2G12 
epitope, permits speculation as to its mode of binding with avidity to HIV spike trimers. 
2G12 has been reported to bind to a specific high-mannose patch on gp120 that has been 
called “intrinsic” due to its conserved and unusual avoidance of a-mannosidase 
processing while being trafficked through the ER and Golgi (Bonomelli et al., 2011). We 
propose that one of the (Fab)2 units of 2G12 dimer first tethers with high affinity to the 
intrinsic mannose patch before sampling the abundant high-mannose landscape in the 
surrounding glycan shield for a second binding opportunity. Because the intrinsic 
mannose patch on an adjacent gp120 monomer within a spike trimer would be too far 
away to be reached by the second (Fab)2 unit of 2G12 dimer, we believe that the second 
2G12 “epitope” would be a suboptimal glycan cluster distinct from the intrinsic mannose 
patch. The finding that 2G12 dimer binds monovalently to immobilized gp120 coupled at 
low density suggests that two (Fab)2 units cannot bind simultaneously to a single gp120, 
and thus the suboptimal second epitope would likely be on an adjacent gp120 within a 
spike trimer.  
 Our studies provide important information for therapeutic anti-HIV efforts in that 
they provide a direct demonstration of the importance of avidity in HIV-1 neutralization. 
Here we show, for the first time, a comparison of the structures of a monomeric and 
dimeric form of a carbohydrate-only anti-HIV-1 antibody. Unlike anti-HIV-1 antibodies 
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against protein-only epitopes, the dimeric form of 2G12 can take advantage of avidity to 
increase its neutralization potency and breadth, and is thus a promising candidate for 
therapeutic efforts to combat HIV-1. Despite initially discouraging results with less 
potent antibodies (Poignard et al., 1999), passive delivery of antibodies has been gaining 
new attention (reviewed in (Klein et al., 2013), with encouraging results from a cocktail 
of five or three highly effective broadly neutralizing antibodies in humanized mice 
infected with HIV-1 (Diskin et al., 2013; Klein et al., 2012). 2G12 dimer would be very 
effectively employed in such a cocktail, as it shares its primary epitope with no other 
known antibody and it can potentially exploit surrounding glycans as a secondary 
epitope. Of direct relevance to potential therapeutic use of antibodies for passive 
immunotherapy, bivalent binding can serve as a buffer against Env mutations (Klein and 
Bjorkman, 2010); thus, 2G12 dimer is a good candidate for therapeutic efforts against 
clade A and clade B HIV strains.  
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EXPERIMENTAL PROCEDURES  
 
Protein expression and purification 
2G12 IgG was expressed in transiently transfected HEK293-6E suspension cells as 
described (West et al., 2009). A mixture of 2G12 monomer and dimer was isolated from 
harvested supernatants by FcRn affinity chromatography (Huber et al., 1993) using 5 mL 
of HiTrap NHS-activated resin (GE Healthcare) coupled to 12 mg of rat FcRn. 
Supernatants were loaded on the FcRn column in 250 mM MES, 150 mM NaCl, 0.02% 
Sodium azide pH 5.7, and eluted in 250 mM HEPES, 150 mM NaCl, 0.02% NaN3 pH 8. 
The eluent was subjected to size-exclusion chromatography in 20 mM Tris pH 8.0, 150 
mM NaCl using a Superdex 200 16/60 gel filtration column (GE Healthcare). Fractions 
corresponding to 2G12 dimer or monomer were pooled and subjected to SEC an 
additional two times to ensure complete separation of 2G12 species.  
Purified monomeric HIV-1 gp120 was a gift from Leo Stamatatos and Zachary 
Caldwell (Seattle BioMed) (Sharma et al., 2006). Purified 2G12 (Fab)2 was a gift from 
Zara Fulton and was imaged by Reza Khayat (The Scripps Research Institute). Other 
reagents, such as control monomeric IgGs and purified soluble rat FcRn (which binds 
human IgG equally as well as rat IgG (Huber, 1994)) were provided by members of the 
Bjorkman laboratory, including Paola Marcovecchio, Han Gao, Maria Politzer, and 
Kathryn Huey Tubman. Protein concentrations were determined spectrophotometrically 
using extinction coefficients at 280 nm of 200480 M-1 cm-1 (2G12 monomer), 400960 M-1 
cm-1 (2G12 dimer), 202000 M-1 cm-1  (conventional monomeric IgG antibodies), 84900 
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M-1 cm-1 (rat FcRn), and 146090 M-1 cm-1 (SF162 gp120). Extinction coefficients were 
calculated based on amino acid compositions using ProtParam (Artimo et al., 2012). 
 
Crystallization and data collection  
Crystals of 2G12 dimer (space group P6122) were grown in hanging drops by mixing 
equal volumes of 2G12 dimer (11.5 mg/ml) with a solution containing 1.2 M ammonium 
sulfate, and 100mM HEPES pH 7.0 at 20º C. Crystals were cryopreserved in well 
solution containing 25-30% glycerol. Data were collected to 7.5 Å resolution at beamline 
8.3.1 of the Advanced Light Source (ALS) at Lawrence Berkeley National Laboratory 
(LBNL), and at beamline 12-2 of the Stanford Synchrotron Radiation Lightsource 
(SSRL) at the SLAC National Accelerator Laboratory. Over 500 crystals were screened, 
but all diffracted poorly and were fragile to handle. Experiments to improve the quality of 
the crystals included seeding, glutaraldehyde crosslinking, recrystallization, additives, 
exchanging into lithium sulfate, exploring cryoprotectants, and varying drop composition. 
Tantalum bromide clusters (Jena Biosciences) were soaked into the native crystals, 
resulting in bright green crystals. SAD data with reflections to 10 Å were collected at 
beamline 8.3.1 of the ALS at LBNL at a single wavelength of 1.255 Å.  
For crystallization of the 2G12 dimer/2G12.1 complex, 2G12.1 peptide (The 
Polypeptide Group) was mixed with 2G12 dimer (11.5 mg/ml) at a 19:1 molar ratio in 
24-well hanging drops of protein and reservoir solution in equal amounts. Clustered 
hexagonal crystals formed from spherolites by vapor diffusion in 5% Tascimate, 10% 
PEGMME 5000, and 100 mM HEPES at pH 7.0. Crystals were cryopreserved in the well 
solution containing 30% PEGMME 5000 and screened at Beamline BL12-2 at the 
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Stanford Synchrotron Radiation Light Source (SSRL) at SLAC, and the 5 µm microbeam 
at beamline 23ID-D at the General Medical Sciences and Cancer Institutes Structural 
Biology Facility (GM/CAT) at the Advanced Photon Source (APS). Upon handling, the 
clustered crystals sometimes disintegrated into smaller, more singular pieces, which were 
also cryoprotected and screened. We also collected usable data sets from large crystals 
(0.3 mm diameter) that contained singular patches.  
 
Data processing and structure determination  
Data were processed using XDS (Kabsch, 2010) or HKL2000 (Otwinowski and Minor, 
1997) and were indexed, integrated, and scaled using POINTLESS and SCALA. We used 
a combination of CC1/2 in the range of 90% (Karplus and Diederichs, 2012) and I/s > 1.5 
in the highest resolution shell to determine the resolution cutoffs for our data sets. Data 
for 2G12 dimer were corrected for anisotropy using the UCLA-MBI Anisotropy Server 
(Strong et al., 2006). Molecular replacement was carried out using Phaser-MR (McCoy et 
al., 2007; Winn et al., 2011) and Molrep (Lebedev et al., 2008; Vagin and Teplyakov, 
2010; Winn et al., 2011). All molecular replacement solutions in space group P6122 
yielded higher translation function Z-scores (10 and above for initial placement of three 
(Fab)2 units) as well as lower initial R factors (0.54 versus over 0.60) than solutions in the 
enantiomeric space group P6522. Model validation calculations using derivative crystals 
were performed using software in the CCP4 Software Suite (Winn et al., 2011) via the 
ccp4i graphical user interface (Potterton et al., 2003): cad (Winn et al., 2011), scaleit 
(Winn et al., 2011), fft (Read, 1988), followed by Phenix.autosol (Adams et al., 2010), 
and Phenix.emma (Adams et al., 2010). Native Patterson calculations were done using 
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POLARRFN (Winn et al., 2011) in the the UCLA-MBI Self Rotation Function Server, 
sfall (Winn et al., 2011) and Patterson (Winn et al., 2011). Rigid body refinement and 
domain B-factor refinement were carried out using CNS (Brunger, 2007; Brunger et al., 
1998) or Phenix.refine (Adams et al., 2010). Model and electron density visualization 
were done using COOT (Emsley et al., 2010) and PyMol (Schroedinger, LLC). Map 
truncation was done using Phenix.map_box (Adams et al., 2010). Structure figures were 
prepared using PyMol. Globular structures in Figures 3, 4, and S4 were prepared by 
conversion of coordinate files into 25 Å mrc map volumes using pdb2mrc in the 
EMAN2.0 suite (Tang et al., 2007), which were then rendered in UCSF Chimera 
(Pettersen et al., 2004). 
 
 
Electron Microscopy (EM) 
2G12 species purified via SEC were analyzed by negative stain EM. A 3 µL aliquot of 1–
2.5 µg/ml of 2G12 (Fab)2 or 2G12 monomer, dimer, or trimer was applied to a freshly 
glow discharged carbon coated 400 Cu mesh grid and stained with 2% uranyl formate for 
20 s. Grids were imaged using a FEI Tecnai T12 electron microscope operating at 120 kV 
at 52,000 x magnification and electron dose of 25 e-/Å2, which resulted in a pixel size of 
2.05 Å at the specimen plane. Images were acquired with a Tietz 4k x 4k CCD camera 
using LEGINON (Suloway et al., 2005) at a defocus range of 700 to 1000 nm. 
Particles were picked automatically using DoG Picker and put into a particle stack 
using the Appion software package (Lander et al., 2009; Voss et al., 2009). Initial 
reference-free 2D class averages were calculated using unbinned particles via the Xmipp 
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Clustering 2D Alignment and sorted into classes (Sorzano et al., 2010). Particles 
corresponding to only 2G12 species were selected into a substack and another round of 
reference-free alignment was carried out using Xmipp Clustering 2D alignment and 
IMAGIC softwares to generate 64 classes (van Heel et al., 1996). A total of 6583, 10341, 
and 4230 particles went into the final 2D classes of the monomer, dimer, and trimer, 
respectively. Back projections of 2G12 IgG dimer A were calculated using EMAN 
software (Tang et al., 2007) as follows: the X-ray coordinates were converted from PDB 
to MRC format using pdb2mrc, low pass filtered to 25 Å resolution to generate a density 
map, and the map was projected at 20° Euler angle increments using project3d and 
displayed in e2display. 
 
Small angle X-ray scattering (SAXS) 
Samples for SAXS were concentrated to 17 mg/ml (2G12 monomer), 13 mg/ml (2G12 
dimer), and 21 mg/ml (Rituximab) and filtered through 0.22 µm membranes. Dialysis to 
buffer exchange each protein into Phosphate Buffered Saline was performed overnight, 
and samples were diluted for a concentration series of 0.25 mg/ml, 0.5 mg/ml, 0.75 
mg/ml, 1.0 mg/ml, 2.5 mg/ml, 5.0 mg/ml, and 7.5 mg/ml, along with 1-3% glycerol to 
minimize aggregation caused by radiation damage. Data were collected at SSRL beam 
line 4-2 using a Rayonix MX225-HE detector at a distance of 2500 mm, using 1.13 Å 
wavelength X-rays. For each concentration of each sample, 15 exposures of 1 second 
were collected, covering a momentum transfer (q) range of 0.0047–0.375 1/Å. The 
scattering profile for the buffer was obtained in the same manner and subtracted from the 
protein profiles. The detector images were integrated, background subtracted, and 
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screened for radiation damage using SasTool (Smolsky, 2007). Extrapolation to infinite 
dilution was done with PRIMUS (Konarev, 2003). Guinier analysis was performed using 
AutoRG, distance distribution functions were determined with GNOM (Svergun, 1992), 
and ab initio reconstructions were performed using DAMMIF (Franke, 2009) and 
DAMAVER (Volkov, 2003) in the ATSAS package (Petoukhov et al., 2012).  
 
Biosensor studies of 2G12 interactions with gp120  
A Biacore T200 biosensor system (GE Healthcare) was used to evaluate the interactions 
of 2G12 monomer, 2G12 dimer, and control anti-gp120 antibodies NIH45-46G54W 
(Diskin et al., 2011) and 2909 (Gorny et al., 2005) with recombinant gp120 from the 
strain SF162 (gift of Leo Stamatatos, Seattle Biomed). Response units (RUs) of gp120 
ranging from fewer than 10 to approximately 100 were covalently immobilized on flow 
cells of CM5 biosensor chips using standard primary amine coupling chemistry (Biacore 
T200 manual, GE Healthcare). A concentration series of either 2G12 monomer, dimer, or 
control anti-gp120 IgG was injected at 25 °C in 10 mM HEPES with 150 mM NaCl, 3 
mM EDTA and 0.005% (v/v) surfactant P20 at pH 7.4. Sensor chips were regenerated 
using 10 nM glycine, pH 2.5. After subtracting the signal from the reference flow cell, we 
globally fit the kinetic data from each experiment to a 1:1 binding model (Biacore 
evaluation software). When an obvious refractive index change occurred when switching 
from the association to the dissociation buffer, the sensorgrams were also fit with a 
refractive index correction (third row, middle panel of Figures 6 and S6). We evaluated 
the fit to the 1:1 binding model of each binding interaction by calculating and plotting 
residuals between the experimental and modeled curves.  
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 Equilibrium gel filtration 
Equilibrium gel filtration chromatography (Hummel and Dreyer, 1962) was performed to 
determine the stoichiometry of the association of 2G12 monomer and 2G12 dimer with 
FcRn. Briefly, chromatography was performed at a flow rate of 100 µL/min using a 
SMART micropurification system (Pharmacia) monitoring the absorbance at 280 nm. 
The experiment was run on a Superdex 200 PC 3.2/30 gel filtration column, which was 
equilibrated with and run in equilibrium buffer (10 mM PIPES, 0.05% Sodium azide, pH 
6.1) containing 5 µM soluble FcRn. All IgG samples and various concentrations of FcRn 
were buffer exchanged into the PIPES buffer via dialysis prior to injection over the 
column. 2.5 µM of 2G12 monomer was mixed with equilibration buffer containing 5 µM 
FcRn plus no additional FcRn, 2.5 uM additional FcRn, 5 µM additional FcRn, or 7.5 µM 
additional FcRn. 1.25 µM of 2G12 dimer was mixed with equilibration buffer containing 
5 µM FcRn plus no additional FcRn, 2.5 uM additional FcRn, 5 µM additional FcRn, or 
7.5 µM additional FcRn.  
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45
FIGURE LEGENDS 
 
Figure 1. Schematic IgG structures 
Heavy chains (identical polypeptide chains, but colored differently for illustrating domain 
swapping) are cyan and yellow, light chains are gray, and antigen binding sites are shown 
as starbursts. (A) Conventional IgG with flexible Fab arms and two antigen binding sites 
at the VH/VL interfaces. (B) 2G12 monomer with domain-swapped (Fab)2 unit and an 
additional antigen binding site at the VH/VH’ interface. (C) 2G12 dimer with two domain-
swapped (Fab)2 units and six antigen binding sites. See also Figure S1.  
 
Figure 2. Packing in 2G12 dimer crystals  
(A) Asymmetric unit of a solvent flattened 8.0 Å resolution 2Fo-Fo electron density map 
contoured at 1.5 σ. The asymmetric unit contained three half-dimers, i.e., three Fc regions 
and three (Fab)2 units from three distinct 2G12 dimers (A, B, and C). Crystal contacts 
involved the antigen binding sites in the (Fab)2 units (green circles); see also Figure S2. 
(B) Application of symmetry operators to generate the second half of each 2G12 dimer. 
Dimer A (cyan) was structurally distinct from Dimers B (magenta) and C (indigo), which 
exhibited the same conformation. (C) Non-crystallographic six-fold symmetry axis 
showing a hexamer of Fc regions coincident with the 61 screw axis along the 
crystallographic c axis. The asymmetric unit is highlighted in yellow. (D) The three 
dimers in one layer of the crystal, represented by the cyan, magenta, and indigo dimers A, 
B, and C (panel B), as they fit into the Fc hexamer ring in panel C; see also Figure S2.  
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Figure 3. Native Patterson validation of packing in 2G12 dimer crystals 
(A,B) Native Patterson maps. Comparison of experimental and calculated Harker 
sections. (C) Two layers of 2G12 dimer molecules as they are packed into the P6122 
crystals. Left: top-down view showing the cyan (dimer A), magenta (dimer B), and 
indigo (dimer C) 2G12 dimers (Figure 2) in the same layer. The magenta and indigo 
dimers are conformationally identical and the cyan dimer is distinct. The layer below 
contains three additional dimers (light green, light pink, and light blue), formed via a 
rotation and translation along the crystallographic 61 axis. Symmetry mates are indicated 
as a darker and lighter version of the same color. Right: a 90º rotation showing hexamer 
of Fc regions in the middle layer. See also Figure S3.  
 
Figure 4. Structures of the three distinct 2G12 dimers from two independent crystal 
structures 
Dimer structures are shown as 25 Å electron density envelopes calculated from (Fab)2 
and Fc coordinates located by molecular replacement. The approximate distance between 
the tips of the (Fab)2 units of each dimer is shown on the left. The symmetry of two of the 
2G12 dimer conformations, dimer A and the dimer in the 2G12/2G12.1 peptide structure 
(panels A and C), was point group C2 (the dimer two-fold symmetry axis was coincident 
with a crystallographic two-fold axis). The dimer B/C conformation (panel B) 
represented a distortion from C2 symmetry. A 2G12 dimer could also have point group 
D2 symmetry with the (Fab)2 units in a similar position as in a C2 dimer except with their 
internal two-fold axes coincident, and with the Fcs above and below the plane of the 
(Fab)2 units with the Fc two-fold axes coincident with each other and perpendicular to the 
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(Fab)2 two-fold axes. Although the D2 conformation appeared plausible, it was not 
observed in our structures. To interconvert these forms would require one (Fab)2 unit to 
rotate 180˚. (A) Dimer A, one of two conformationally-distinct 2G12 dimers in the P6122 
2G12 dimer structure. Middle and Right: Heavy chains are cyan and yellow, light chains 
are transparent gray. Middle: Top-down view of the 2G12 dimer with Fc regions pointing 
into the page. Right: Two rotated views showing the large distance between (Fab)2 units 
and Fc regions and an angle of 180º between (Fab)2 arms. (B) Dimers B and C, the 
second of the two distinct 2G12 dimers in the P6122 2G12 dimer structure. Middle and 
Right: Heavy chains are magenta, indigo, light pink, or light blue; light chains are 
transparent gray. Middle: Top-down view of the 2G12 dimer molecule with Fc regions 
pointing into the page. Right: Two rotated views showing an obtuse angle between (Fab)2 
units. (C) 2G12 dimer in crystals of 2G12 bound to the 2G12.1 peptide. Middle and 
Right: Heavy chains are orange, green, light orange, or light green; light chains are light 
gray. Middle: Top-down view. The two (Fab)2 units are extended at 180° with respect to 
each other, as are the two Fc regions (not seen in this view). Right: Two rotated views 
showing the Fc regions under the (Fab)2 units. See also Figure S4.  
 
Figure 5. Negative stain EM of 2G12 oligomers 
Representative two-dimensional class averages (left) and false-colored images (right) of 
2G12 (Fab)2, 2G12 monomer, 2G12 dimer, and 2G12 trimer showing the orientations of 
the domain-exchanged (Fab)2 units and the Fc regions. Fabs are colored in cyan and Fcs 
in yellow. Bar = 10 nm. (B-D) 2D class averages of 2G12 oligomers analyzed by 
negative stain EM. Bar = 10 nm. Panels of 64 class averages of the (B) 2G12 monomer, 
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(C) 2G12 dimer, and (D) 2G12 trimer generated using reference-free Xmipp Clustering 
2D alignment. (E) Back projections sampled at 20˚ Euler angles of the low-pass filtered 
2G12 Dimer A crystal structure. Bar = 10 nm. Many of the back projections resembled 
the reference-free class averages of the 2G12 IgG dimer in panel C. See also Figure S5 
for SAXS data supporting the EM and crystallographic results. 
 
Figure 6. Surface plasmon resonance-based binding studies 
Sensorgrams were derived from binding experiments in which 2G12 monomer, 2G12 
dimer or a conventional monomeric anti-gp120 IgG was injected over immobilized 
gp120 from HIV-1 strain SF162. Experimental data (colored lines) were fit to a 1:1 
binding model (black lines). Residual plots are shown in Figure S6. (A) 2G12 monomer, 
2G12 dimer, and a conventional anti-gp120 IgG (NIH45-46G54W) injected over gp120 
immobilized at high coupling density (~100 RU). 2G12 monomer, but not 2G12 dimer or 
the conventional IgG, could be fit to a 1:1 binding model. (B) 2G12 monomer, 2G12 
dimer, and a conventional anti-gp120 IgG (NIH45-46G54W) injected over gp120 
immobilized at medium coupling density (~50 RU). 2G12 monomer, but not 2G12 dimer 
or the conventional IgG, could be fit to a 1:1 binding model. (C) 2G12 monomer, 2G12 
dimer, and a conventional anti-gp120 IgG (2909) injected over gp120 immobilized at low 
coupling density (<10 RU). All could be fit to a 1:1 binding model.  
 
Figure 7. Equilibrium gel filtration analyses of FcRn-2G12 complexes 
 (A) FcRn was incubated with 2.5 µM 2G12 monomer in the presence of 0, 1, 2, or 3 
(additional) equivalents of FcRn in a buffer containing 5 µM FcRn (equilibration buffer). 
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Samples were then injected onto a column equilibrated in the equilibration buffer. The 
peak that eluted first corresponded to an FcRn-2G12 monomer complex. The second 
peak or trough was at the elution volume of free FcRn. (B) FcRn was incubated with 1.25 
µM 2G12 dimer in the presence of 0, 2, 4, or 6 (additional) equivalents of FcRn in a 
buffer containing 5 µM FcRn (equilibration buffer). Samples were then injected onto a 
column equilibrated in the equilibration buffer. The peak that eluted first corresponds to 
an FcRn-2G12 dimer complex. The second peak or trough was at the elution volume of 
free FcRn. 
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SUPPLEMENTAL RESULTS 
 
Calculation of interchain distances for connectivity model for 2G12 dimer/2G12.1 
peptide complex 
Nineteen residues within the 2G12 hinge region were missing from the (Fab)2 (pdb ID 
1OP3) and Fc (pdb ID 1H3X) structures used as search models for molecular 
replacement. Distances from the N-termini of the four Fc polypeptide chains to the C-
termini of the four (Fab)2 heavy chains were measured using coordinates for high 
resolution models placed into the 2G12 dimer/2G12.1 structure for residues Pro-238 (N-
terminus of Fc) and Lys-228 (C-terminus of the (Fab)2 heavy chain) (residue numbering 
based on the structures of 2G12 (Fab)2 (pdb ID 1OP3) and Fc (pdb ID 1H3X)).  
 
Solution studies of 2G12 monomer and 2G12 dimer  
Small-angle X-ray scattering (SAXS) can be used to derive ab initio information about 
the size, shape, and flexibility of proteins in solution (Putnam et al., 2007). To obtain 
independent structural information for 2G12 dimer, we used SAXS to investigate the 
conformational range of 2G12 dimer (Figure S5). We obtained X-ray scattering profiles 
(Figure S5E) from solutions of purified 2G12 monomer, 2G12 dimer, and Rituximab, a 
conventional monomeric human IgG (Anderson et al., 1997). For each protein, we 
generated 10 ab initio models (Figure S5A-C) using DAMMIF (Franke, 2009), which 
were superposed, averaged, and filtered using DAMAVER (Volkov, 2003). Models filled 
with dummy atoms showed 2G12 monomer as a relatively rigid “slab” with potential 
flexibility only at the hinge region between the (Fab)2 unit and the Fc (Figure S5A). In 
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contrast, models of 2G12 dimer showed a larger molecule with increased conformational 
flexibility (Figure S5B). Rituximab models showed a thinner but conformationally 
similar molecule to 2G12 dimer (Figure S5C).  
The distance distribution function P(r) was derived through an indirect Fourier 
transform of the scattering curve using GNOM (Svergun, 1992). P(r) was monomodal for 
2G12 monomer and 2G12 dimer (Figure S5D), corresponding to the profile for a globular 
protein. P(r) for Rituximab exhibited a smaller second peak, suggesting the presence of 
more elongated domains in solution (Figure S5D) (Putnam et al., 2007). P(r) functions 
for all three proteins converged smoothly to zero at Dmax, which corresponded to the 
maximum linear dimension of the scattering particles: 162 Å for 2G12 monomer, 178 Å 
for Rituximab, and 193 Å for 2G12 dimer. The differences in apparent size in solution 
corroborated our findings from the crystal structures of 2G12 dimer: as predicted, the 
gyration space that 2G12 dimer occupied in solution was larger than that of both 2G12 
monomer and Rituximab. 2G12 monomer, which should exhibit limited mobility due to 
the (Fab)2 domain exchange, indeed had a lower Rg than both conventional IgG and 2G12 
dimer (Guinier analysis yielded Rg values of 46 ± 0.42 Å, 52 ± 2.3 Å, and 59 ± 0.67 Å, 
for 2G12 monomer, Rituximab, and 2G12 dimer, respectively; see Figure S5D). 
Rituximab also exhibited a broader Rg distribution in Guinier analysis than both 2G12 
monomer and dimer, suggesting that the conventional IgG was more flexible in solution 
than 2G12 dimer. 2G12 dimer was in turn more flexible than 2G12 monomer, which 
exhibited the narrowest Rg distribution. The reference model chosen by DAMAVER 
produced a .fir file in DAMMIF, which was used to calculate a back-transform of the 
final averaged models (Figure S5E). Simulated scattering from the averaged models fit 
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the experimental scattering data well, with χ2 of fit values between Iexp and Isim of 1.347, 
1.202, and 1.218 for 2G12 monomer, 2G12 dimer, and control IgG Rituximab, 
respectively (Figure S5E).  
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SUPPLEMENTAL EXPERIMENTAL METHODS 
 
Protein expression and purification 
Purified monomeric HIV-1 gp120 was a gift from Leo Stamatatos and Zachary Caldwell 
(Seattle BioMed) (Sharma et al., 2006). Purified 2G12 (Fab)2 was a gift from Zara Fulton 
and was imaged by Reza Khayat (The Scripps Research Institute). Other reagents, such 
as control monomeric IgGs and purified soluble rat FcRn (which binds human IgG 
equally as well as rat IgG (Huber, 1994)) were provided by members of the Bjorkman 
laboratory, including Paola Marcovecchio, Han Gao, Maria Politzer, and Kathryn Huey 
Tubman. Protein concentrations were determined spectrophotometrically using extinction 
coefficients at 280 nm of 200480 M-1 cm-1 (2G12 monomer), 400960 M-1 cm-1 (2G12 
dimer), 202000 M-1 cm-1  (conventional monomeric IgG antibodies), 84900 M-1 cm-1 (rat 
FcRn), and 146090 M-1 cm-1 (SF162 gp120). Extinction coefficients were calculated 
based on amino acid compositions using ProtParam (Artimo et al., 2012). 
 
Crystallization and data collection 
Crystals of 2G12 dimer (space group P6122) were grown in hanging drops by mixing 
equal volumes of 2G12 dimer (11.5 mg/ml) with a solution containing 1.2 M ammonium 
sulfate, and 100 mM HEPES pH 7.0 at 20º C. Crystals were cryopreserved in well 
solution containing 25-30% glycerol. Data were collected to 7.5 Å resolution at beamline 
8.3.1 of the Advanced Light Source (ALS) at Lawrence Berkeley National Laboratory 
(LBNL), and at beamline 12-2 of the Stanford Synchrotron Radiation Lightsource 
(SSRL) at the SLAC National Accelerator Laboratory. Over 500 crystals were screened, 
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but all diffracted poorly and were fragile to handle. Experiments to improve the quality of 
the crystals included seeding, glutaraldehyde crosslinking, recrystallization, additives, 
exchanging into lithium sulfate, exploring cryoprotectants, and varying drop composition. 
Tantalum bromide clusters (Jena Biosciences) were soaked into the native crystals, 
resulting in bright green crystals. SAD data with reflections to 10 Å were collected at 
beamline 8.3.1 of the ALS at LBNL at a single wavelength of 1.255 Å.  
For crystallization of the 2G12 dimer/2G12.1 complex, 2G12.1 peptide (the 
Polypeptide Group) was mixed with 2G12 dimer (11.5 mg/ml) at a 19:1 molar ratio in 
24-well hanging drops of protein and reservoir solution in equal amounts. Clustered 
hexagonal crystals formed from spherolites by vapor diffusion in 5% Tascimate, 10% 
PEGMME 5000, and 100 mM HEPES at pH 7.0. Crystals were cryopreserved in the well 
solution containing 30% PEGMME 5000 and screened at beamline BL12-2 at the SSRL 
at SLAC, and the 5 µm microbeam at beamline 23ID-D at the General Medical Sciences 
and Cancer Institutes Structural Biology Facility (GM/CAT) at the Advanced Photon 
Source (APS). Upon handling, the clustered crystals occasionally disintegrated into 
smaller, more singular pieces, which were also cryoprotected and screened. We also 
collected usable data sets from large crystals (0.3 mm diameter) that contained singular 
patches.  
 
Model validation calculations 
Calculations using derivative crystals were performed using software in the CCP4 
Software Suite (Winn et al., 2011) via the ccp4i graphical user interface (Potterton et al., 
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2003): cad (Winn et al., 2011), scaleit (Winn et al., 2011), fft (Read, 1988), followed by 
Phenix.autosol (Adams et al., 2010), and Phenix.emma (Adams et al., 2010). 
 
Small angle X-ray scattering (SAXS) 
Samples for SAXS were concentrated to 17 mg/ml (2G12 monomer), 13 mg/ml (2G12 
dimer), and 21 mg/ml (Rituximab) and filtered through 0.22 µm membranes. Dialysis to 
buffer exchange each protein into Phosphate Buffered Saline was performed overnight, 
and samples were diluted for a concentration series of 0.25 mg/ml, 0.5 mg/ml, 0.75 
mg/ml, 1.0 mg/ml, 2.5 mg/ml, 5.0 mg/ml, and 7.5 mg/ml, along with 1-3% glycerol to 
minimize aggregation caused by radiation damage. Data were collected at SSRL 
beamline 4-2 using a Rayonix MX225-HE detector at a distance of 2500 mm, using 1.13 
Å wavelength X-rays. For each concentration of each sample, 15 exposures of 1 second 
were collected, covering a momentum transfer (q) range of 0.0047–0.375 1/Å. The 
scattering profile for the buffer was obtained in the same manner and subtracted from the 
protein profiles. The detector images were integrated, background subtracted, and 
screened for radiation damage using SasTool (Smolsky, 2007). Extrapolation to infinite 
dilution was done with PRIMUS (Konarev, 2003). Guinier analysis was performed using 
AutoRG, distance distribution functions determined with GNOM (Svergun, 1992), and 
ab initio reconstructions were performed using DAMMIF (Franke, 2009) and 
DAMAVER (Volkov, 2003) in the ATSAS package (Petoukhov et al., 2012).  
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Supplemental Table  
Table S1. Data Collection and Refinement Statistics 
 
 
2G12 dimer 
2G12 dimer with 
(Ta6Br12)2+ 
2G12/2G12.1 
peptide 
Data Collection 
 
   
Resolution (Å) 39.8-8.0 (8.3-
8.0) 
35.0-10.0 (10.34-
10.0) 
64.9-6.5 (6.7-6.5) 
Space group P612 2 P612 2 P6 
Unit cell a = b = 246 Å  
c = 657 Å 
a = b = 250 Å  
c = 652 Å 
a = b = 375 Å  
c = 64 Å 
α = β = 90°  
γ = 120° 
α = β = 90°  
γ  = 120° 
α = β = 90°  
γ = 120° 
Total reflections 26016 (2520) 90570 113124 (11045) 
Unique reflections 12654 (1260) 11087 (483) 10665 (1022) 
Completeness (%) 96.95 (71.03) 99.0 (89.6) 99.96 (100.00) 
Mean I/σ(I) 6.51 (1.72) 7.6 (1.3) 7.84 (1.51) 
Rmerge 0.088 (0.46) 0.33 (0.78) 0.28 (2.1) 
CC½   0.99 (0.80)  1.0 (0.83) 
CC* 1.0 (0.94)  1.0 (0.95) 
Ranom  0.22 (0.87)  
Anomalous completeness  74.6 (74.4)  
Anomalous multipicity  4.6 (4.7)  
f'  -26.4  
f"  17.0  
    
Refinement 
 
   
Rwork 0.35 (0.35)  0.38 (0.44) 
Rfree 0.37 (0.36)  0.36 (0.39) 
Number of atoms 29250  28984 
Protein residues 3795  3750 
RMS bonds (Å) 0.018  0.037 
RMS angles (°) 1.62  1.78 
Average B-factor (Å2) 159.0  481.0 
*Statistics for the highest-resolution shell are shown in parentheses. 
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Supplemental Figure Legends 
 
Figure S1. Proposed connectivities of 2G12 dimer and 2G12 trimer, related to 
Figure 1 
 (A,B) Schematic diagrams illustrating how intermolecular domain swapping could lead 
to 2G12 dimer (A) and 2G12 trimer (B). The connectivity model allows for the formation 
of higher order multimers, including tetramers (panel C). (C) Size exclusion 
chromatography profile for 2G12 proteins after elution from an FcRn affinity column. 
Peaks labeled as monomer and dimer were identified using in-line static light scattering 
to determine their molecular masses (West et al., 2009). Peaks migrating at higher 
apparent molecular weights are labeled as trimer and tetramer. 
 
Figure S2. Heavy atom validation of molecular replacement phases, related to 
Figure 2 
Data were collected from crystals of 2G12 dimer soaked with tantalum bromide clusters 
to 10 Å resolution at a wavelength of 1.255 Å, chosen to maximize the anomalous 
diffraction signal of tantalum. Using phases derived from the molecular replacement 
model, we calculated both anomalous and isomorphous difference Fourier maps, which 
each yielded a set of peaks, seven of which were common to both maps. We checked the 
top five potential heavy atom sites by iteratively omitting one site, calculating phases 
with the remaining sites, and then examining difference Fourier maps to see if the 
omitted site was found. Two of the five potential sites, iteratively omitted in this way, 
were independently reproduced. In each calculation of an isomorphous difference Fourier 
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map during cross-phasing, three additional sites were consistently and independently 
produced. One site was reproduced in the calculations of anomalous difference Fourier 
maps during cross-phasing. We concluded that the three sites that survived the cross-
phasing process after appearing consistently in both isomorphous and anomalous 
difference Fourier maps corresponded to tantalum bromide clusters. The putative 
tantalum bromide sites corresponded to locations on the surface of the 2G12 dimer 
model. (A) Heavy atom sites (colored spheres) on dimer B/C from Figure 2. (B) Heavy 
atom sites on dimer A from Figure 2.  
 
Figure S3. Packing of 2G12/2G12.1 peptide crystals, related to Figure 3 
Half of a unit cell containing three copies of the asymmetric unit in space group P6 is 
shown. The asymmetric unit contains one intact 2G12 dimer (two (Fab)2 units and two 
Fcs; yellow Ca trace) and half of a second 2G12 dimer (one (Fab)2 unit and one Fc; 
magenta Ca trace). Rotation around a crystallographic two-fold axis creates the second 
half of the magenta dimer, which is conformationally the same as the yellow dimer. (A) 
Green circles show locations of antigen binding sites, which do not contact each other in 
the P6 crystals. Addition of 2G12.1 peptide to 2G12 dimer disrupted the crystal contacts 
at the antigen binding sites in the P6122 2G12 dimer crystals (Figure 2A). (B) Blue 
circles highlight crystal contacts between Fc regions. Similar crystal contacts were found 
in the P6122 2G12 dimer crystals (Figures 2C, 3C). (C) 2G12/2G12.1 structure shown as 
a volume representation (Figure 4C) superimposed on the locations of the yellow dimers 
(left) and magenta dimers (right). 
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 Figure S4. Distinct 2G12 dimer structures, related to Figure 4 
Dimer structures are shown as 25 Å electron density envelopes calculated from (Fab)2 
and Fc coordinates located by molecular replacement calculations. Side indicates dimers 
shown with side views of (Fab)2 units, top indicates a view in which Fc regions point into 
the page, and bottom indicates a view in which Fc regions point out of the page. (A) 
Dimer A from Figure 2 (cyan) (Figure 4A). (B) Dimers B and C from Figure 2 (magenta 
and indigo) (Figure 4B). (C) Dimer from 2G12/2G12.1 peptide structure (Figure 4C). 
The symmetry of two of the 2G12 dimer conformations, dimer A and the dimer in the 
2G12/2G12.1 peptide structure (panels A and C), was point group C2 (the dimer two-fold 
symmetry axis was coincident with a crystallographic two-fold axis). The dimer B/C 
conformation (panel B) represented a distortion from C2 symmetry. A 2G12 dimer could 
also have point group D2 symmetry with the (Fab)2 units in a similar position as in a C2 
dimer except with their internal two-fold axes coincident, and with the Fcs above and 
below the plane of the (Fab)2 units with the Fc two-fold axes coincident with each other 
and perpendicular to the (Fab)2 two-fold axes. Although the D2 conformation appeared 
plausible, it was not observed in our structures. To interconvert these forms would 
require one (Fab)2 unit to rotate 180˚. 
 
Figure S5. SAXS Data for 2G12 monomer, dimer, and a conventional IgG 
monomer, related to Figure 5 
Ab initio models filled with dummy atoms revealing size and shape of (A) 2G12 
monomer, (B) 2G12 dimer, and (C) Rituximab, a conventional IgG monomer. (D) Pair-
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distribution functions and Guinier plots from 2G12 monomer, dimer, and Rituximab. 
Guinier plots calculated from low q ranges behaved linearly, indicating minimal 
aggregation (Hammel, 2012; Mertens and Svergun, 2010). Differences in Dmax calculated 
from P(r) were consistent with 2G12 monomer’s comparatively smaller range of motion 
and Rituximab’s more freely mobile domains compared to 2G12 dimer. (E) Data 
analyses. Left: Scattering profiles of 2G12 monomer, 2G12 dimer, and Rituximab, 
plotted as log(I) vs. q. Profiles from all concentrations of each protein were 
superimposable when scaled by concentration, indicating low inter-particle forces, 
properly folded species, and ideal sample quality. Accordingly, one representative 
scattering profile was chosen from the concentration series for each individual protein, 
and merging of multiple scattering profiles was not required. Second from left: 
Traditional Kratky analysis used for detecting conformational flexibility via visual 
inspection (Putnam et al., 2007). Bimodal profiles for 2G12 dimer and Rituximab 
revealed behavior similar to that of a heterogeneous mixture of species. 2G12 dimer 
exhibited a slowly increasing curve at large q values, suggesting an elongated species 
when compared to Rituximab and 2G12 monomer. Third from left: Analysis of samples 
using Porod-Debye law revealed a loss of plateau in Rituximab when compared with 
2G12 monomer, indicating increased flexibility. 2G12 dimer exhibited a divergent curve 
at large q values, characteristic of an elongated species (Hammel, 2012). Right: 
Simulated scattering from DAMAVER averaged models (red, green, or blue) fit to the 
experimental scattering data (gray), plotted as log(I) vs. q. 
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Figure S6. SPR sensorgrams containing residuals of 1:1 binding model fits, related 
to Figure 6 
Sensorgrams were derived from binding experiments in which 2G12 monomer, 2G12 
dimer, or a conventional monomeric anti-gp120 IgG was injected over immobilized 
gp120 from HIV-1 strain SF162. Experimental data (colored lines) were fit to a 1:1 
binding model (black lines). Residual plots are shown in Figure S6. (A) 2G12 monomer, 
2G12 dimer, and a conventional anti-gp120 IgG (NIH45-46G54W) injected over gp120 
immobilized at high coupling density (~100 RU). 2G12 monomer, but not 2G12 dimer or 
the conventional IgG, could be fit to a 1:1 binding model. (B) 2G12 monomer, 2G12 
dimer, and a conventional anti-gp120 IgG (NIH45-46G54W) injected over gp120 
immobilized at medium coupling density (~50 RU). 2G12 monomer, but not 2G12 dimer 
or the conventional IgG, could be fit to a 1:1 binding model. (C) 2G12 monomer, 2G12 
dimer, and a conventional anti-gp120 IgG (2909) injected over gp120 immobilized at low 
coupling density (<10 RU). All could be fit to a 1:1 binding model.  
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   Chapter 3 
Structure of an HIV-2 gp120 envelope glycoprotein in complex with CD4 
 
Introduction 
Human immunodeficiency virus type 1 (HIV-1) remains a threat to global public health. 
With no vaccine available, it disproportionately causes acquired immunodeficiency 
syndrome (AIDS) in the developing world. While the related virus HIV-2 is still capable 
of causing full-blown AIDS, infection rates are more localized and on the decline (de 
Silva et al., 2008; Kong et al., 2012a; Kong et al., 2012b). In contrast to patients infected 
with HIV-1, the majority of HIV-2 patients remain asymptomatic with low plasma viral 
loads and normal CD4+ T cell counts (Berry et al., 1998; Jaffar et al., 1997; van der 
Loeff et al., 2010). HIV-2 is a robust immunogen in natural infection, and patients 
generally make high titer, broadly reactive, and very strongly neutralizing antibodies 
against primary strains – something rarely seen in HIV-1 infection (de Silva et al., 2008; 
Kong et al., 2012a; Kong et al., 2012b). In addition, neutralizing antibodies emerge 
readily after HIV-2 infection, whereas this process in HIV-1 can take many years (Kong 
et al., 2012a; Kong et al., 2012b). In spite of the presence of a robust immune response, 
HIV-2 appears slower to evolve the neutralization-resistant variants so commonly found 
in HIV-1 infections (de Silva et al., 2008; MacNeil et al., 2007). For cohorts in the same 
population, vertical transmission of HIV-2 via breastfeeding from mother to child without 
antiretroviral therapy (ART) is less than 4%, compared with over 24% for HIV-1 
(O'Donovan et al., 2000).  
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  The bulk of current investigative efforts in the HIV field are focused on HIV-1 
due to its high virulence and transmissibility. However, the immune response in the 
context of HIV-2 infection may provide a natural model of effective HIV control. While 
HIV-2 is not an attenuated virus, infected patients seem to naturally exhibit 
characteristics of a desired response to an effective therapy against HIV-1. Therefore, a 
deeper understanding of the immune response against HIV-2 should reveal insight into 
the missing pieces required to elicit a similar response against HIV-1. While the features 
of an “ideal” immune response remain unclear, a study of patient serum dually infected 
with HIV-1 and -2 (HIV-D) found that neutralizing activity existed only against HIV-2 
(Schim van der Loeff et al., 2002). This suggests the presence of distinct and divergent 
immune responses against these related viruses. In addition, HIV-2 is more closely 
related to Simian Immunodeficiency Virus (~80% amino acid identity in envelope 
glycoprotein) than it is to HIV-1. Therefore, knowledge about HIV-2 pathogenicity in the 
context of an immune response can inform our understanding of ongoing studies using 
SIV and simian-human immunodeficiency virus (SHIV)-macaque infection models 
(Kong et al., 2012b).  
HIV-1 and HIV-2 share 30% sequence identity and 40% amino acid identity in 
their envelope glycoprotein (env) gp160 (Kong et al., 2012a; Kong et al., 2012b; Kwong 
et al., 1998). Much has been uncovered over the last 30 years about the role of the HIV-1 
env as an antigen, with a wealth of recent insight from its sensitivity to broadly-
neutralizing antibodies. Env is the only known target of such antibodies, and 
understanding its interactions with the immune system is invaluable for rational 
immunogen and prophylactic design. Infected patients have the capability to make 
91
	  antibodies against many epitopes on gp120: the variable loops, the conserved CD4 
binding site, the CD4i or co-receptor binding site, various glycans, and the membrane 
proximal region of gp41, among others (Kwong and Mascola, 2012). 10-20% of these 
HIV-1 infected subjects are able to make broadly neutralizing antibodies in low titers, 
and these have been the subject of intense study, structural and otherwise. Despite the 
high sequence identity between HIV-1 and HIV-2, neutralizing antibodies generally do 
not cross-react between the two viruses outside of a few highly conserved epitopes 
(Decker et al., 2005; Kong et al., 2012a). 
Despite the growing collection of HIV-1 gp120 and gp140 trimer structures from 
X-ray crystallography and electron microscopy, no structures of HIV-2 gp120 exist. To 
investigate possible explanations for its decreased pathogenicity and increased 
immunogenicity compared with HIV-1, we solved the structure of a HIV-2 gp120 core 
from the ST strain in complex with the first two domains of the CD4 host receptor. ST 
gp120 exhibits only ~35% sequence identity with HIV-1 gp120 strains, and we compared 
it here to known HIV-1 gp120 core crystal structures with or without CD4 bound. It is 
our hope that this represents the first of many structural studies of HIV-2 envelope 
glycoprotein, as insights gained from this natural form of HIV viral control may inform 
therapy and immunogen design for HIV-1.  
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  Results 
Crystallization of the HIV-2 gp120 core with sCD4 D1D2 
Sequences for gp120 from strains HIV-2UC1, HIV-2ST, HIV-27312A-0303, and HIV-27312A-
9217 were obtained from the Los Alamos National Laboratory HIV Sequence Database 
(http://www.hiv.lanl.gov/). These strains were chosen based on availability and 
completeness of sequences as well as demonstrated sensitivity to newly isolated anti-
HIV-2 gp120 monoclonal antibodies with known epitopes. As no previous structures of 
HIV-2 gp120 exist, we attempted to create crystallization constructs adapted from the 
HIV-1 gp120 core convention: deletions of the V1/V2 and V3 variable loops as well as a 
portion of the C-terminus (Kwong et al., 1998). While the HIV-2 sequences align 
unambiguously with HIV-1 gp120, we have no information about the importance of 
glycans attached to potential N-linked glycosylation sites in the folding process of HIV-2 
gp120. Therefore, we only mutated one conserved site (T89I) distal from predicted 
binding interfaces.  
After screening several combinations of anti-HIV-2 and anti-HIV-1 antibody Fab 
fragments, CD4 N-terminal domains D1 and D2 (sCD4 D1D2), and HIV-2 gp120 cores 
from different strains, we obtained crystals of HIV-2 gp120 core from the ST strain in 
complex with sCD4 D1D2. Co-crystals of gp120/CD4 diffracted to 2.5 Å resolution at 
the SSRL beamline 12-2, with collected data usable up to 3.0 Å as indicated by the CC½  
statistic (Karplus and Diederichs, 2012). Data were processed using XDS, and crystals 
were in space group C2221 with unit cell dimensions of a=94.276, b=100.223, c=199.139 
(Table 1). Using high-resolution structures for sCD4 D1D2 (pdb ID 2NXY, 100% 
sequence identity) and core HIV-1 gp120 CAP210 (pdb ID 3LQA, 36% sequence 
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  identity) as search models, Phaser (McCoy et al., 2007) successfully placed gp120 by 
molecular replacement. Upon fixing this partial solution, sCD4 was placed at the 
expected location for engaging gp120, with one gp120/sCD4 complex in the asymmetric 
unit. Prior to rebuilding, initial refinement of the molecular replacement model resulted in 
Rwork/Rfree values of 42%/48%, indicative of significant discrepancies between the search 
model and data. Many rounds of manual rebuilding and refinement were performed, 
which were complicated by low data quality and poor electron density maps in various 
regions. In all, 46 out of 339 residues in the HIV-2 gp120 core and 31 out of 181 residues 
in sCD4 D1D2 were disordered. The D2 domain of sCD4 exhibited especially poor 
density, as it lacked stabilizing crystal contacts. Manual rebuilding was guided by a 
simulated annealing composite omit map to minimize model bias (Brunger and Rice, 
1997), and the final structure was refined to Rwork/Rfree values of 24.5%/29.8% (Table 1).  
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Table 1. Data collection and refinement statistics. 
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  Figure 1. Sequence alignment showing numbering convention for gp120ST. ST 
numbering is according to SIVMM239 convention (Calef, et al, 2001, Los Alamos HIV 
Sequence Compendium) except where indicated in green. Insertions in SIVMM239 
relative to ST are shown in red. Insertion in ST relative to SIVMM239 is shown in green. 
Blue highlighting indicates crystallographic truncations. HXB2 is included for reference.  
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  Structural overview of HIV-2 gp120 core 
The core HIV-2 ST gp120 structure comprises 23 β-strands (β1-23), four a-helices (α1-4), 
five loop regions A-E, truncated variable loops V1-3, and disordered V4 and V5 loops. 
Six conserved disulfide bonds were clearly visible in electron density and superimposed 
well with disulfides in other HIV-1 gp120 core structures. Nine putative N-linked 
glycosylation sites (ST numbering according to SIVMAC239 convention, see Figure 1) – 
N212, N244, N278, N284, N295, N306, N404, N460, and N479 (N197, N229, N263, 
N269, N280, N291, N389, N446, and N464 in HXB2 numbering, respectively) showed 
visible density for sugar residues (Figure 2). Only two of these (N263HXB2 and N389HXB2) 
are also glycosylation sites in 93TH057 gp120. The overall architecture of ST gp120 was 
nearly identical to that of other HIV-1 gp120s. Superposition with HIV-1 gp120s resulted 
in Cα backbone R.M.S.D. values between 1.5-1.6 Å. Inner and outer domains could be 
unambiguously assigned (Figure 2). There were no notable global conformational or 
secondary structure deviations from existing HIV-1 gp120 structures, though potentially 
significant local differences exist. 
Beginning with the inner domain (Figure 2), no visible density was seen for the 
first seven residues of the N-terminus, and a short seven-residue region (Figure 2, yellow) 
of the β-2 strand was placed into density by unambiguous superposition with 93TH057 
gp120 from pdb 3U7Y (corresponding to residues 51-57 in 93TH057/HXB2). The intact 
trace begins at residue D63ST (D81HXB2), three residues earlier than the start of the 
original HxBc2 gp120 core structure (Kwong 1998). β-strands 1-8 and α-1 helix were 
well aligned to HIV-1 gp120, with some discrepancy between ST and 93TH057 at the 
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  stumps of the truncated V1/V2 loop. The loop region between β-3 and β-4 in ST 
corresponding to the putative position of the disordered α-0 helix clashed with the loop 
regions around the position of α-0 helix in 93TH057 gp120, indicating a possible 
alternative conformation for this helix in ST gp120.  
In the outer domain (Figure 2, mint green), secondary structure elements 
remained well aligned to HIV-1 gp120. Loops C and D were both slightly offset from 
their counterparts in 93TH057. It has been postulated that HIV-2 has a more open V3 
loop conformation than HIV-1 due to HIV-2 having fewer potential N-linked 
glycosylation sites (Shi et al., 2005). 
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Figure 2. Structural overview of HIV-2 gp120 in cartoon representation, with modeled 
glycans as sticks. Outer domain is in mint green, inner domain is in yellow, pink, 
lavender, raspberry, and gray. Disordered loops are represented by dashed lines. Glycan 
residues are shown in ball-and-stick representation and numbered according to ST and 
HXB2 convention.  
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  However, the ST structure has a truncated V3 stem with the same number of residues as 
93TH057 from pdb 3U7Y and ten more residues than the original HxBc2 gp120 structure 
from pdb 2NXY. The ST and 93TH057 V3 stems of equal length superimpose with 
RMSD = 0.46 Å, so the discovery of any differences between HIV-1 and HIV-2 would 
require future comparison of structures with an intact V3 loop. Loop E in HIV-2 gp120 is 
three to five residues longer than in HIV-1, and features a turn not seen in HIV-1 gp120 
structures. The V4 and V5 loops in the ST structure, which in HIV-2 are shorter and less 
glycosylated than in HIV-1, were completely disordered. 	  
  
Figure 3. Sequence of ST gp120 crystal structure showing only ordered residues. 
Secondary structure (shown above sequence) and contacts with CD4 (indicated below 
bars by black or red letter “B” on yellow background, non-italicized). Disordered 
residues are shown as “X” in the sequence. Relative accessibility “acc” is indicated in the 
bar directly below the sequence: white is buried, cyan is intermediate, and blue is 
accessible. Hydropathy “hyd” is indicated in the lowermost bar below the sequence: pink 
is hydrophic, gray is intermediate, and cyan is hydrophilic.  
100
	  Comparison to CD4-bound and unbound HIV-1 gp120 structures   
The ST gp120/CD4 structure superimposed with HIV-1 gp120/CD4 structures using 
sequence-based alignment in PyMOL (The PyMOL Molecular Graphics System, 
Schrödinger, LLC) with RMSD between 1.5-1.6 Å (Figure 5). ST gp120 contacted CD4 
at the residues expected from HIV-1 gp120/CD4 co-crystal structures (specifically, 
residues 278-281HXB2, 365-6HXB2, 370-371HXB2, 373-374HXB2, 425-430HXB2, 455-456HXB2, 
472-474HXB2, and 480HXB2 (Figure 3). 
Analysis of structural and sequence conservation between ST gp120 and the top 
seven most similar HIV-1 gp120 core structures in the PDB (4DVR, 3TGR, 1G9N, 3U7Y, 
4JM2, 2NY0, 1GC1) using EndScript (Robert and Gouet, 2014) showed high degrees of 
sequence similarity (75 identical residues) and structural conservation in most regions 
except for structured loops (Figure 4A and 4B). Loops V3, V4, V5, and E exhibit 
especially high sequence and structural variation.  
A comparison of the ST/CD4 structure to three HIV-1 gp120/CD4 structures 
revealed no notable difference in the molecular interfaces of CD4 binding to HIV-2 
gp120 (Ca backbone R.M.S.D. values ~1.6 Å) (Figure 5A). Loop D in HIV-2, which 
makes close contacts with CD4, is shifted and conformationally distinct from loop D in 
HIV-1 (Figure 5B). Notably, position 280HXB2/295ST in all HIV-1 and HIV-2 features a 
conserved asparagine, but position 297ST/282HXB2 in HIV-2 is a threonine, making 
N295ST/N280HXB2 a potential N-linked glycosylation site. Figure 5C shows the position 
of N280 in aligned HIV gp120 structures, showing that N280 in ST is in a shifted 
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  location relative to HIV-1. There was no appreciable difference between the loop D of 
the CD4-bound (pdb 4P9H) or unbound (pdb 3U7Y) versions of 93TH057 gp120.  
 
Figure 4A. Analysis of structural and sequence conservation. ST gp120 compared to 
seven gp120 cores in the Protein Data Bank of highest sequence similarity to ST. Thin 
sausage indicates high structural similarity, and thick sausage indicates high structural 
deviation. Red indicates high sequence conservation (identity), and white indicates high 
sequence variation (lower limit 0.7% equivalent, see Endscript). Identical residues 
between all eight gp120s are shown in blue stick representation. Sequence alignment 
from EndScript (Robert and Gouet, 2014) using all eight gp120s is shown below in 
Figure 4B.  
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Figure 4B. Sequence alignment of ordered residues in ST gp120 core crystal structure to 
seven HIV-1 gp120 cores. Identical residues are in red, similar residues in yellow. ST 
numbering according to SIVMAC239 convention.  
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Figure 5. Overlays of gp120s and gp120/CD4 structures. (A) Alignment of ST/CD4 
with three HIV-1 gp120/CD4 complex structures and one free gp120 structure. (B) ST 
loop D is slightly shifted from most HIV-1 loop Ds, especially when oriented by the 
position of conserved residue N280HXB2 (C). (D) The ST CD4-binding loop with a 
portion represented as dashes due to structural disorder. (E) ST loop E is three to five 
residues longer in HIV-2 than in HIV-1. 
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  The CD4-binding loop in ST gp120 was partially disordered, but alignment of 
ordered residues with HIV-1 CD4-binding loops suggested a similar conformation 
(Figure 5D). As expected from these observations, the side chain of residue F43 on CD4 
fits into a hydrophobic pocket on HIV-2 gp120 (Figure 6A), as observed for the “Phe43” 
pocket in HIV-1 gp120 structures (Kwong et al., 1998). Key residues important for CD4 
binding are intact and identical to those in HIV-1 gp120/CD4 complex structures (Figure 
6B). 
	  
Figure 6. CD4 binding site on ST gp120. (A) The side chain of CD4 F43 (gray cartoon 
representation) inserts itself into a hydrophobic pocket of gp120 (mint surface 
representation), identical to CD4 binding in HIV-1 gp120. (B) Key residues in CD4 
binding to HIV-2 gp120 are conserved and nearly identical to those for binding to HIV-1 
gp120. Aligned with HXB2/CD4 from pdb 2NXY (RMSD = 1.503 Å).  
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  One of the most distinct structural differences between HIV-2 and HIV-1 gp120 is 
the extended Loop E of HIV-2 gp120. Loop E is three to five residues longer in HIV-2 
and originates from the junction between the α-2 helix and β-14 strand in the ST/CD4 
structure. In alignments with Loop E from HIV-1 gp120 (Figure 5E), Loop E from ST 
was longer and potentially more flexible, bending down toward the rest of the gp120 
rather than adopting an extended conformation.  
Some HIV-2 isolates have been shown to enter cells in a CD4-independent 
manner (Thomas et al., 2003), leading to the hypothesis that HIV-2 may have a more 
open co-receptor binding domain (de Silva et al., 2008). At least for the CD4-bound state, 
the co-receptor binding footprint of ST gp120 is virtually identical to that of other HIV-1 
gp120s (Figure 7). 
 
Figure 7. Co-receptor binding footprint in ST gp120 and HIV-1 gp120 structures. 
gp120 backbone trace in ribbon representation, co-receptor footprint in surface 
representation, Key residues from (Decker et al., 2005).  
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  Comparison with unliganded SIV gp120 structure  
Full-length ST gp120 has 72% sequence identity with SIVmac32H gp120, the strain 
whose unliganded crystal structure was previously solved (Chen et al., 2005a, b). The 
sequence alignment of both crystal structures is shown in Figure 8B. Despite the high 
level of conservation between SIV and HIV-2 full length gp120s (Figure 9), ST gp120 
aligned poorly with the unliganded SIV gp120 structure (RMSD = 5.2 Å for 863 
backbone Ca atoms), and molecular replacement using the unliganded SIV gp120 
structure as a search model yielded no solutions. The β-strands that compose the bridging 
sheet are shifted by ~13-25 Å with the V1/V2 loops ~ 27 Å apart, potentially due to 
differences caused by CD4 binding. Helix α-1 is shifted by 15 Å, and the three-stranded 
β-sheet at the C-terminus is offset by a 90° rotation (Figure 8A).   
 
Figure 8A. Sequence based structure alignment of ST gp120 to unliganded SIV gp120 
from pdb 2BF1, chain A (RMSD = 5.2 Å).  
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Figure 8B. Alignment of ST crystallization construct and SIV crystallization construct. 
Conservation, secondary structure, hydropathy, and contacts of ST crystallization 
construct.  
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Figure 9. Sequence alignment of HIV-2ST gp120 to other HIV-2 gp120s. 
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  Discussion 
The structure of ST gp120 in complex with CD4 represents the first structural 
characterization of an HIV-2 envelope glycoprotein. While its overall architecture is 
nearly identical to that of HIV-1 gp120, our observation of differences between the two 
viruses at the molecular level is the first step toward mechanism-revealing structural 
studies. In 2013, Shaw and colleagues isolated and mapped the epitopes of 14 new 
monoclonal antibodies against several epitopes on HIV-2 gp120 (Kong et al., 2012a; 
Kong et al., 2012b). These antibodies were found to be broadly reactive against the CD4 
binding site, CD4i co-receptor site, and the V3 and V4 loops, and can serve as valuable 
tools for structural studies. Studying the behavior of neutralizing antibodies against HIV-
2 and their epitopes on the virus can shed light on HIV-2 as an antigen inciting an 
effective and appropriate immune response – insights that can also be relevant to efforts 
to understanding HIV-1 as well as SIV and SHIV models.  
Systematic investigations of HIV-2 gp120 in complex with antibody antigen 
binding fragments (Fabs) are the clear next step. Ideally, a series of co-crystal structures 
with gp120-Fab complexes will reveal a comprehensive epitope map on the surface of 
HIV-2 gp120. Co-crystals with CD4i antibodies will provide additional insight into the 
co-receptor binding site, since the possibility of a more open conformation in that region 
is intriguing given the ability of some HIV-2 isolates to infect cells without engaging 
CD4. Concurrent with HIV-2 gp140 trimer studies using negative stain electron 
microscopy (see Chapter 4), these HIV-2 complex structures can be docked into 3D 
reconstructions created from gp120-Fab complexes to gain insight into quaternary 
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  epitopes or intermolecular interactions within the spike trimer. HIV-2 native trimer may 
exhibit differences in overall conformation compared to HIV-1.  
Given the difference in pathogenicity between HIV-1 and HIV-2 (de Silva et al., 
2008) and the highly distinct unliganded SIV gp120 structure (Chen et al., 2005b), we 
expected a larger discrepancy between the gp120 structures of the two human viruses. 
While the observed similarities do not explain the difference in virulence between HIV-1 
and HIV-2, they allow us to begin ruling out potential sources. Differential immune 
activation may result from significant differences in the variable loops, which are 
truncated or disordered in the current structure. Fewer potential N-linked glycans, and 
thus, decreased glycan shielding, of the V3 and V4 loops in HIV-2 could lead to higher 
immunogenicity in those areas (Shi et al., 2005). The present crystallization construct 
could be improved upon with GlySer linkers in place of simple truncations of variable 
loops. Attempts could also be made to crystallize the gp120 core with variable loops left 
intact.   
Due to the robust neutralizing antibody response to HIV-2, it is likely that the 
difference in pathogenicity is due, at least in large part, to the role of the envelope 
glycoprotein. This is encouraging for the potential future growth of HIV-2 knowledge, as 
the HIV field has long been focused and is well equipped for conducting comprehensive 
structural studies of the interactions between Env and its binding partners. We still lack 
basic molecular descriptions of the relationship between HIV-2 and the human immune 
system, so it is compelling to imagine other possibilities for differences outside of the 
Env glycoprotein. HIV-2 is a desirable target for investigation to the scientific 
community, as it represents a model of naturally attenuated HIV infection, a long-pursued 
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  target. Patients infected with HIV-2 benefit from a feedback loop: for unknown reasons, 
they make effective antibodies against Env, which results in a well-controlled infection 
and a better-preserved, less-suppressed immune system. This in turn enables a more 
robust and effective immune response. This suggests that HIV-1 exploits the breakdown 
of any step in this feedback loop for its own mechanisms of immune evasion, which 
emphasizes the importance of therapies that interfere with the neutralizing antibody 
binding step of the immune response. In an unknown fashion, HIV-2 remains a fit virus, 
able to bring some patients to full-blown AIDS and yet seems to maintain a low mutation 
rate in the face of neutralizing antibodies. Our lack of understanding of this balance 
reveals potential holes in our knowledge of basic principles in HIV biology, and further 
structural studies of HIV-2 will undoubtedly uncover new solutions to this problem.  
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  Experimental methods  
Construct design, subcloning, protein expression and purification of recombinant gp120 
for crystallization. Sequences for gp120 from strains HIV-2UC1, HIV-2ST, HIV-27312A-0303, 
and HIV-27312A-9217 were obtained from the Los Alamos National Laboratory HIV 
Sequence Database. These strains were chosen based on availability and completeness of 
sequences as well as demonstrated sensitivity to newly isolated anti-HIV-2 gp120 
monoclonal antibodies with known epitopes. For each strain, constructs were designed 
with deletions of the V1/V2 and V3 variable loops, as well as 15 residues from the C-
terminus (GFAPTPVKRYSSAPVRNKR). The N-terminus was left intact. We made only 
one mutation at T89I and left all other glycosylation sites intact. Using gblock (Integrated 
DNA Technologies) assembly via PCR and restriction enzymes EcoRI and NotI (New 
England Biolabs), all four genes were subcloned into pTT5-CMV vectors and expressed 
in N-acetylglucosaminyltransferase I (GnTI) deficient mammalian cells to limit glycan 
processing. All constructs contained secretion peptide 
MDAMKRGLCCVLLLCGAVFVSPAGAGS, and secreted gp120 protein was harvested 
from cell supernatants. Gp120 was purified via Ni-NTA affinity chromatography and 
further purified via size exclusion chromatography (SEC) on a Superdex200 16/60 
column.  
          Of the four strains, ST and 7312A-9217 exhibited unimodal SEC profiles. Strain 
7312A-0303, despite being a closely related variant of 7312A-9217, formed apparent 
multimers over SEC. Strain UC1 expressed poorly in mammalian cells, and a 
baculovirus/SF9 expression of full-length UC1 yielded multimers over SEC. As a result, 
7312A-9217 and ST gp120 were purified and concentrated by centrifugation to 12-16 
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  mg/ml. As a binding partner to be used in co-crystallization, domains D1 and D2 of 
soluble CD4 were expressed and purified from baculovirus-infected SF9 cells. At the 
time, we did not have access to any of the new anti-HIV-2 gp120 monoclonal antibodies. 
Anti-HIV-1 antibody 21c binds to the co-receptor site on gp120 after the conformational 
change induced by CD4 engagement. A co-crystal of 21c Fab, sCD4 D1D2, and a core 
CAP210 gp120 was published by Ron Diskin from our lab in 2009 (Diskin et al., 2010). 
In his studies, he found that 21c also bound to UC1, an HIV-2 strain. A study (Decker et 
al., 2005) exploring the conservation of the co-receptor site suggested that many CD4-
induced (CD4i) antibodies against HIV-1 gp120, including 21c, were able to neutralize or 
bind to HIV-2 gp120. While the paper did not explicitly state that 21c interacted with the 
strain ST, we proceeded to use 21c Fab in co-crystallization trials with sCD4 D1D2 and 
both ST and 7312A-9217. 21c IgG was expressed in and harvested from supernatants of 
HEK293-6E mammalian cells and purified via Ni-NTA affinity and size exclusion 
chromatography. IgG was cleaved into Fab fragments using a Papain cleavage kit 
(Thermo) while uncleaved IgG was purified away using Protein A beads.  
Complex formation, purification, and crystallization of gp120. To form complexes, 2 mg 
gp120, equimolar sCD4 D1D2, and initially 21c Fab in slight molar excess were 
combined and allowed to incubate at room temperature for 1 hour. The preps were treated 
with Endo H for 16 hours at room temperature and purified over a Superdex 200 10/300 
size exclusion column. Both ST and 7312A-9217 appeared to form stable complexes with 
their binding partners over SEC, but ST yielded the highest complex peak and was 
chosen for crystallization trials after concentration to A280 ~ 10-12. A small amount of the 
7312A-9217 complex peak was concentrated but was rendered unusable after aggregating 
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  readily. 21c Fab eluted separately during size-exclusion chromatography and did not bind 
to ST gp120, so it was not included in the crystal screening despite being in the original 
prep. To check for the presence of any 21c Fab binding to the gp120/CD4 complex, 
fractions from the SEC trace were run on an SDS-PAGE gel, but as 21c Fab and ST ran 
at the same position, it was not apparent if 21c was in the complex. ST gp120 ran as a 
smear consistent with heterogeneous glycosylation. Soluble CD4 D1D2 appeared to be 
unambiguously present in the complex. Peaks were pooled and concentrated for 
crystallization trials. Crystals formed via sitting drop vapor diffusion in 3-4 days in 
0.15M DL-Malic acid 7.0, 0.1M imidazole 7.0, and 22% PEGMME 550. The crystals 
were readily reproducible after being scaled up into 600nl + 600nl hanging drop trays. 
Since a complex with ST and sCD4 D1D2 alone co-purified over SEC yielded the same 
crystals, it was determined that these were the only two components of the co-crystals.  
Data collection, processing, and molecular replacement calculations of gp120/sCD4 
D1D2 structure. For data collection, crystals were cryopreserved in either mother liquor 
containing 30% glycerol or Fomblin oil. The latter resulted in higher resolution 
diffraction. Crystals diffracted to up to 2.5 Å at the SSRL beamline 12-2, with collected 
data usable up to 3.0 Å decided by CC1/2. Data were processed using XDS, and crystals 
were in space group C2221 with unit cell dimensions of a=94.276, b=100.223, c=199.139, 
a=90, b=90, g=90. Using high resolution structures for sCD4 D1D2 (pdb ID 2NXY) and 
core HIV-1 gp120 CAP210 (3LQA) as search models in Phaser-MR, molecular 
replacement yielded no solutions containing both components. Upon fixing partial 
solutions containing only gp120, sCD4 was placed at the expected location for engaging 
gp120. Initial refinement of the model resulted in Rwork/Rfree values of 0.42/0.48, and 2Fo-
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  Fc maps for the resultant model containing sCD4 D1D2 and gp120 were generally poor, 
since the two gp120s share only 35% sequence identity.  
Refinement of gp120/sCD4 D1D2 structure. The structure of gp120/sCD4 D1D2 was 
manually rebuilt in Coot guided by a simulated annealing composite omit map calculated 
using CNS (Brunger, 2007) or Phenix.autosol (Adams et al., 2010) in conjunction with 
the 2Fo-Fc map. Many iterative rounds of refinement were performed using Phenix.refine 
(Adams et al., 2010), including but not limited to rigid body, group B-factor, TLS, real-
space, and Rosetta-guided refinement algorithms (Adams et al., 2013). The final structure 
was re-refined using Refmac (Murshudov et al., 1997) within the PDB_REDO server 
(Joosten et al., 2014).  
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  Chapter 4 (Unpublished work in progress) 
Making a soluble, cleaved, native-like HIV-2 gp140 trimer 
Introduction 
Human immunodeficiency virus (HIV) infects host CD4+ T cells via its envelope 
glycoprotein (Env), which is the key to viral fusion mediated by host receptors CD4 and 
CCR5/CXCR4. Full length Env glycoprotein gp160 is synthesized and proteolytically 
cleaved intracellularly into gp120 and gp41 using host machinery, and then trafficked to 
the viral surface upon maturation. The Env complex comprises a trimer of heterodimers: 
three gp120-gp41 subunits held together noncovalently after cleavage (Poignard et al., 
2001). For many years, structural studies of HIV Env have focused on the gp120 or gp41 
core fragments, which can be prepared stably using recombinant methods. These 
fragments generally corresponded to the CD4-bound, post-fusion state of Env, which is 
not as informative as the prefusion configuration that initially encounters the immune 
system. While these studies have revealed details of the interaction between HIV and the 
immune system, they are lacking in their interrogation of the native trimeric infectious 
unit. Studies of the trimer could lead to more effective vaccine targets, as many known 
non-neutralizing monoclonal antibodies against HIV-1 only bind to monomeric Env and 
not to trimeric Env . It is likely that the immune system reacts differently to trimeric Env 
versus nonnative, non-intact fragments of the trimer, such as dissociated gp120 or poorly 
formed gp160 trimers. The latter events likely result in nonproductive interactions in 
which antibodies are made against epitopes irrelevant for HIV neutralization. For these 
reasons, an HIV trimer that can mimic the native, cleaved conformation while remaining 
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  stable when expressed recombinantly would be valuable for both structural and 
immunological studies.  
Due to the labile nature of the noncovalent gp120-gp41 interaction, recombinant 
production of fully posttranslationally processed trimers were problematic for many years 
(Sanders et al., 2002). An intermolecular disulfide bond (SOS) was introduced with 
mutations at A501C and T605C in order to covalently link gp120 and the gp41 
ectodomain (gp41ECTO). Full length gp160 was truncated just before the membrane-
proximal region, resulting in gp140. Oligomeric SOS gp140 could be transiently 
expressed in HEK 293T cells (Sanders et al., 2002), but its purification resulted in gp140 
monomers, indicating a loss of integrity at the trimerization interface despite 
improvement of the gp120-gp41ECTO association. To stabilize the trimerization interface, 
an isoleucine-to-proline (IP) mutation was introduced at position 559 (Binley et al., 2000; 
Sanders et al., 2002) to destabilize the post-fusion configuration and therefore enhance 
stability of the prefusion configuration, which is of highest biological interest given that 
most existing structures feature the postfusion form of Env. This specific I to P mutation 
was effective at coercing SOS gp140 to trimerize more reliably in the prefusion form 
over a number of other mutations at other sites (Sanders et al., 2013; Sanders et al., 2002). 
This version of Env was dubbed “SOSIP,” and it formed native-like, soluble, cleaved, 
noncovalently associated trimers.  
In 2013, a “next-generation” version of SOSIP trimers of subtype A strain BG505 
was shown to preferentially bind neutralizing antibodies (Sanders et al., 2013). These 
stable and native-like trimers featured a truncation at position 664 of the gp41 
transmembrane domain (just prior to the MPER) and a cleavage-enhancing mutation of 
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  REKR to RRRRR at the Furin proteolytic site between gp120 and gp41(Sanders et al., 
2013). These trimers are generally co-expressed with soluble Furin protease, which 
performs the cleavage (Sanders et al., 2002). BG505 SOSIP.664 trimer eluted via size-
exclusion chromatography with a prominent trimer peak along with a smaller monomer 
peak. The trimer peak could be re-purified and used for further studies. As a result, 
crystal and cryo-EM structures of this protein were published to 4.7 Å and 5.8 Å 
resolution, respectively (Julien et al., 2013; Lyumkis et al., 2013). Both structures were in 
agreement with respect to the overall architecture of the soluble trimer, and they revealed 
crucial interactions between gp120 and gp41 as well as between the gp120 subunits. The 
BG505 SOSIP.664 trimer represents a new, native-like standard for studying the function 
of the HIV envelope spike during host infection as well as provides crucial insight for 
immunogen and prophylactic design.  
For similar motivations, we sought to create and describe the analogous trimeric 
envelope glycoprotein from HIV-2. As previously discussed, the formidable body of 
knowledge that has accumulated surrounding HIV-1 Env does not exist for HIV-2. 
Therefore, it remains uncertain whether any observed differences in pathogenicity and 
virulence between the two viruses derive from differences in Env. To obtain a stable, 
native-like HIV-2 trimer protein analogous to BG505 SOSIP.664 gp140 from HIV-1, we 
will initially introduce the identical SOSIP modifications to HIV-2 gp140 glycoproteins 
from various strains. If successful, characterization of this protein with or without binding 
partners (e.g., CD4, MAbs) via electron microscopy, X-ray crystallography, and other 
biophysical methods will provide insight into the native behavior of HIV-2 virions in the 
context of host infection and subsequent immunological response. Comparative studies 
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  between the HIV-1 and HIV-2 versions of soluble, native trimers will further elucidate 
the differences in their pathogenicities.  
Initial design of HIV-2 SOSVP trimers 
We first obtained all available full-length HIV-2 gp160 sequences from the Los Alamos 
HIV Sequence Database (HIV Sequence Compendium 2013). We then chose the most 
complete sequences that were in agreement with GenBank depositions, resulting in three 
strains as candidates for creating HIV-2 trimers: 7312A, UC1, and ST (see Figure 3.1 for 
sequence alignment). We included cysteine mutations to add the engineered SOS 
disulfide bond between gp120 and gp41, as well as a valine (isoleucine in HIV-1) to 
proline mutation to promote trimerization. We named these constructs HIV-2 “SOSVP” 
gp140 trimers (Figure 3.2). The REKR Furin cleavage site (consensus with HIV-1) was 
initially mutated to RRRR (4R) to enhance proteolytic cleavage (Binley et al., 2002; 
Sanders et al., 2013). The original BG505 SOSIP.664 constructs contained a mutation to 
RRRRRR (6R) in lieu of the original Furin cleavage site. Since very little was known 
about making HIV-2 soluble Env trimers, we sought to be conservative and created both 
4R and 6R mutants. The sequence was truncated at position 664 to exclude the 
transmembrane domain of gp41 (Figure 3.2). The constructs also contained a C-terminal 
Gly-Ser linker and a His6 tag to facilitate Ni-NTA affinity purification.  
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Figure 3.1 Sequence alignment of HIV-1/2 gp160, cont’d on next page.  
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Figure 3.1, cont’d. Annotated alignment of WT BG505, SOSIP BG505, and four WT 
HIV-2 gp160 sequences (sequence after MPER not shown). 
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Figure 3.2 Schematic of HIV-2 gp140 Env trimers. Native features are shown in black, 
and modifications to wild-type are shown in red or blue. R(N/H)KR indicates native 
Furin cleavage site in HIV-2 gp160, 4R or 6R indicates Furin cleavage enhancing 
mutations. V559P is analogous to I559P “IP” mutation in HIV-1 SOSIP trimers. 
Mutations for additional SOS disulfide bond are indicated. G4S linkers completely 
substitute for Furin cleavage site in “NFL” or GS trimers. All G4S-containing trimer 
constructs were not co-transfected with sFurin.  
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  Biochemical analysis of purified HIV-2 SOSVP protein  
Elution fractions from size-exclusion chromatography were initially analyzed via 
Coomassie blue and silver stained SDS-PAGE gels. The elution profile exhibited peaks 
for what appeared to be multimeric, trimeric, and monomeric states (Figure 3.3). 
Coomassie blue stain for both 7312A SOSVP and UC1 SOSVP of boiled, non-reduced 
fractions revealed that the trimeric state migrated as a single band, indicating that the 
engineered disulfide bond was behaving properly. However, the non-reduced band ran at 
an apparent molecular weight greater than 250 kDa, while the boiled, reduced fractions 
ran at an apparent lower molecular weight, around 140 kDa. This is in contrast to the 
BG505 SOSIP trimer, which ran at 140 kDa non-reduced and 120 kDa reduced (as 
expected from the name gp140 and gp120). The gp41ECTO domain, which should run 
between 25 to 37 kDa for a reduced sample, was not stained by Coomassie blue. We 
silver stained these samples but saw no evidence of a cleavage product around that size, 
with the same result for a BG505 SOSIP positive control (data not shown). In addition, 
we performed a Western blot with anti-His6 tag antibody to check for the cleavage 
product, since the His6 tag should migrate with the gp41 portion on a reducing gel if 
cleavage occurred as expected and if the SOS disulfide bond was broken under reducing 
conditions. This Western blot, shown in the top panel of Figure 3.4, suggests that 7312A 
SOSVP 4R and UC1 SOSVP 4R were not cleaved. In this analysis, BG505 SOSIP 
gp41ECTO did give a signal between 25 to 37 kDa as a positive control. In an attempt to 
make the cleaved version of HIV-2 SOSVP trimers, the original RRRR enhanced Furin 
cleavage site in the 7312A SOSVP and UC1 SOSVP contructs were mutagenized to 
RRRRRR (6R). The resulting HIV-2 trimers were purified as previously stated. The SEC 
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  profile once again exhibited multimer, trimer, and monomer peaks (Figure 3.3), and the 
trimer peak was isolated for analysis via SDS-PAGE. For both UC1 SOSVP 4R and 6R 
proteins, the first elution from Ni-NTA affinity chromatography exhibited a higher 
population of monomeric gp140 when subjected to size-exclusion chromatography 
(Figure 3.3 bottom panel, solid blue trace). A second pass of supernatant containing 
gp140 over the Ni-NTA column resulted in a higher fraction of trimeric gp140 (dotted 
blue trace), indicating a difference in Ni-NTA affinity between oligomers, potentially 
resulting from differences in accessibility to the C-terminal His6-tag. Coomassie blue 
staining of boiled, non-reduced, and boiled, reduced SOSVP 6R trimer fractions appeared 
identical to their SOSVP 4R counterparts (data not shown here). An anti-His6 Western 
blot of the SOSVP 6R fractions showed ambiguous results (Figure 3.4, bottom panel). 
Fraction A6 or A7, which corresponded to trimeric protein for UC1 or 7312A SOSVP 6R 
respectively, did not appear to show cleavage due to the absence of the gp41ECTO band 
under reducing conditions (lanes 2 and 6). This band did appear for Fractions A11 and 
A12 (lanes 4 and 8), which corresponded to monomeric gp140. However, there is also 
some evidence of signal for the non-reduced samples of those fractions, which could have 
occurred as a result of contamination between lanes. At most, these results suggest that 
SOSVP 6R gp140 monomers may be cleaved, but that gp140 trimers were not cleaved.  
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Figure 3.3 Size-exclusion chromatography elution profile of 7312A and UC1 SOSVP 
4R and 6R gp140 trimers. Trimers migrated around 9-10 ml, monomers ran around 12 
ml, and the void volume of the S200 10/300 was around 8 ml.  
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Figure 3.4 Anti-His6 western blot for 7312A SOSVP 4R (top), 6R (bottom) and UC1 
SOSVP 4R (top), 6R (bottom). Indicated fractions from SEC elution of proteins were 
boiled in buffer with and without DTT for reducing and non-reducing conditions, 
respectively. The samples were run on AnyKD (BioRad) SDS-PAGE gels and transferred 
to nitrocellulose for western blotting with anti-His6 tag antibody.    
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  Analysis of purified HIV-2 SOSVP RRRR (4R) protein via SEC-MALS. 
To determine the oligomeric states of various fractions in the SEC elution of HIV-2 
SOSVP 4R trimer proteins, a size exclusion chromatography system (AKTA, GE) was 
coupled in-line with a UV detector, a multi-angle light scattering (MALS) detector, a 
quasi-elastic light scattering (QELS) detector, and a refractive index (RI) detector (Wyatt 
Technologies). We characterized the molar mass of the entire glycoprotein using the RI 
signal (both carbohydrate and protein contributions). The results (see Table 3.1) indicated 
that fractions A8 and A9 of the 7312A SOSVP 4R trace and that fraction A6 of the UC1 
SOSVP 4R trace (see Figure 3.3) were likely HIV-2 trimers. This measurement does not 
distinguish between a cleaved or an uncleaved trimer, as both have the same molar mass. 
 
Table 3.1 SEC-MALS analysis of HIV-2 SOSVP 4R trimers. Highlighted values 
correspond to the molar mass of trimeric gp140, in agreement with BG505 SOSIP trimers 
(1 and 2 from (Depetris et al., 2012)). 
 
132
	  Analysis of the HIV-2 SOSVP trimers via negative stain electron microscopy  
Negative stain EM has been used as an assay to study the overall behavior and 
appearance of HIV-1 soluble trimers (Georgiev et al., 2015; Sanders et al., 2013; Scharf 
et al., 2014). Native-like, well-behaved, cleaved trimers generally appear as unaggregated, 
consistently compact single particles amenable to 3D reconstruction (Ringe et al., 2013). 
To perform this analysis on HIV-2 SOSVP trimers, we used a T12 electron microscope to 
image negatively stained (using 2% uranyl acetate) 4R and 6R proteins (at 0.01 mg/ml) 
adsorbed onto glow-discharged holey carbon grids.  
7312A and UC1 SOSVP 4R trimers appeared aggregated and heterogeneous, 
often forming filament-like structures (Figure 3.5, left panels). This may have been 
caused by inherent instability of the uncleaved trimers or adverse reactions of the proteins 
to staining. 7312A and UC1 SOSVP 6R trimers (Figure 3.5, right panels) appeared more 
homogeneous in particle size, although we could not locate many particles with the 
distinctive trimeric shape by visual inspection (i.e., presence of a three-fold rotational 
axis). There was a great deal of protein “debris” evident on the SOSVP 6R grids, which 
could have been caused by the grids not having been made using fresh protein preps. 
Staining technique could also be a factor, as the standard procedure calls for waiting for 
the grid to dry completely during the protein adsorption step. Proteins with inherent 
instability may suffer from drying and destruction of morphology before the stain is 
applied, so from this point we began to apply stain when the grid was still slightly wet 
(Alasdair McDowell, personal communication).  
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Figure 3.5 Negative stain electron micrographs of 7312A and UC1 4R (left) and 6R 
particles (right). Protein samples were purified via Ni-NTA affinity chromatography 
followed by size-exclusion chromatography. Fractions from the latter were taken and 
diluted to 0.01 mg/ml.  
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  Design, mutagenesis, protein expression and purification of non-SOSVP HIV-2 
gp140 trimers.  
Since neither HIV-2 SOSVP 4R nor 6R trimers appeared ideal from Western blot and 
EM results, we pursued a new rationale for construct design. Given that little is known 
about HIV-2 Env in general, literature was consulted for both HIV-2 and for SIV, its 
most closely related virus. In addition, given the known differences between HIV-1 and -
2, we hypothesized that the SOSIP mutations that were optimized for HIV-1 may not be 
appropriate for creating well-behaved HIV-2 trimers. Soluble, wild-type HIV-1 gp140 
trimers have historically been difficult to obtain (Broder et al., 1994; Earl et al., 1994; 
Earl et al., 1992; Earl et al., 1991). SIV gp140 trimers, on the other hand, were readily 
expressed in the Lec3.2.8.1 system (Chen et al., 2000). Zhang, et al created a chimeric 
gp140 protein (Zhang et al., 2001) using HIV-1 strain ADA gp120 and SIV mac32H 
gp41 ectomain which was reproducibly stable with no additional alterations that were 
typically used for making soluble HIV gp140 trimers (e.g., engineered disulfide bond, 
GCN4 leucine zipper). These results support the possibility that HIV-2 trimers could 
potentially be expressed stably as wild-type, without SOSIP-like modifications. 
The rationale for the SOS mutation is to covalently link the cleaved gp120 and 
gp41ECTO, and the IP mutation is to destabilize the gp41-gp41 postfusion interface to 
promote the stability of the prefusion configuration of Env trimers. The postfusion state 
of SIVmac Env has been shown to be less stable than that of HIV-1 Env (Liu et al., 2002; 
Sanders et al., 2002), and the Tm of SIV gp41 (40°C) is lower than that of HIV-1 gp41 
(66°C) (Malashkevich et al., 1998). From these results, we infer that HIV-2 Env may also 
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  be inherently destabilized in its gp41 region compared to HIV-1 Env, and may not need 
the V to P mutation (I to P in HIV-1) for further destabilization (Center et al., 1997).   
  With these insights, we designed two new sets of HIV-2 gp140 trimer constructs 
(see Figure 3.2). The first set began with reversion of all SOSVP-related mutations to 
wild-type, with or without RRRRRR (6R) proteolytic enhancement. We then added back 
SOS or VP mutations alone, again with or without 6R. The rationale here was to capture 
the point at which any of these mutations, if at all, became relevant for optimization of 
soluble HIV-2 gp140 trimer production.  The second set of constructs did not have the 
SOS mutation but used a flexible GGGGSGGGGS linker in place of the native Furin 
cleavage site, since the space resulting from cleavage allows the resultant gp120 and 
gp41 to fall into their native conformation within the trimer. A sufficiently long GS linker 
would serve the same purpose, and it has been shown to effectively make “native flexible 
linker” (NFL) trimers (Sharma, et al., 2015)(Georgiev et al., 2015) that are well behaved 
trimers in a native-like conformation. NFL trimers contain both the linker as well as the I 
to P (V to P in HIV-2) mutation. We also created a version without the V to P mutation, 
called GS WT. Several of these constructs were expressed and purified as previously 
stated, and their SEC elution profiles are shown in Figure 3.6. Most of the proteins 
featured a taller trimer peak (centered around fractions A6 or A7), with a shorter 
multimer or aggregate peak running slightly larger. There was little to no evidence of 
gp140 monomers, in contrast to results for the previous SOSVP 4R or 6R proteins. 
Coomassie blue stained gels of a few representative elutions are shown in Figure 3.7. 
These constructs looked similar to previous sets of constructs on non-reducing SDS-
PAGE, but the samples under reducing conditions showed an additional band 
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  corresponding to roughly 140 kDa. This band was previously not seen on gels of SOSVP 
4R or 6R (Figure 3.4) but was evident in reduced BG505 SOSIP controls on the same gel. 
Figure 3.6 Size-exclusion chromatography elution profile for initial HIV-2 new 
trimers. Trimers generally ran around 9-10 ml, monomers ran around 12 ml, and 
aggregates ran around 8 ml. ST GS VP “NFL” gp140 (magenta curve) was run on a 
different AKTA, so the fraction markers (in red) are slightly offset relative to that of the 
other samples (in light green).  
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Figure 3.7 Example of SDS-PAGE analysis of initial HIV-2 new trimers. Samples 
under reducing conditions exhibit a new band at 140 kDa, corresponding to a gp140 
monomer.  
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  Analysis of non-SOSVP HIV-2 trimers via negative stain electron microscopy 
Several non-SOSVP constructs were analyzed by negative stain EM as previously 
described (a few examples shown in Figure 3.8, top panels). Overall, the morphologies of 
these newer trimer constructs were consistently better than HIV-2 SOSVP trimers upon 
visual inspection. 7312A GS WT particles looked especially promising, as they were 
more compact and homogeneous than previous HIV-2 constructs, with distinguishing 
features instead of an amorphous mass. 1,600 particles were picked from around 100 
images for reference-free 2D class averages (Figure 3.8, bottommost panel). The 
presence of several classes whose signals did not converge indicated that the sample was 
still not appropriate for 3D reconstruction. However, several classes exhibited a three-
fold axis of symmetry indicating possible trimers (Figure 3.8, last row).  
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Figure 3.8 Example of negative stain electron micrographs of new trimers with 
initial 2D class averages from 1,600 particles of 7312A GS WT gp140.  
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  Discussion and future directions 
Over the last few decades, the majority of efforts to make a native-like, soluble, readily 
expressed, cleaved gp140 trimer has been applied to HIV-1. Recently, this work has 
culminated in the long-awaited X-ray and EM structures of an intact HIV-1 trimer (Julien 
et al., 2013; Lyumkis et al., 2013). The potential impact of the insight gained from these 
structures is enormous, and we were motivated by similar reasons to pursue the 
analogous target in HIV-2. A well-behaved, trimeric HIV-2 gp140 would lend itself to 
structural studies to answer compelling questions about its apparently lower 
pathogenicity and virulence. In our initial efforts, mimicking the mutations optimized for 
HIV-1 SOSIP.664 trimers proved to be a generally unproductive strategy. Though the 
two are closely related, HIV-2 Env trimer likely exhibits inherent, even if subtle 
differences in stability and conformation compared to HIV-1. We have yet to fully 
appreciate these distinguishing features in HIV-2, so designing new constructs starting 
from the wild-type version of HIV-2 gp140 may provide a promising route. Currently, 
our best lead is the 7312A GS WT construct, which has reproducibly appeared compact 
and homogeneous when analyzed via negative stain EM. Several strategies can now be 
employed to further improve this and other constructs to obtain a more useful reagent for 
studying native-like HIV-2 Env trimers.  
The first step should be performing additional EM analyses of 7312A GS WT 
using fresh protein, wet-stained sample, and minimally handled grids to prevent bending. 
Experimenting with stain optimization and grid washing may also benefit the quality of 
particles. 7312A GS WT should also be purified in complex with CD4 and/or Fabs from 
anti-HIV-2 antibodies to enhance 2D class averaging of particles. The next step should be 
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  a comparative study of all the proteins from the constructs listed in Figure 3.2. We have 
purified protein for all versions of the 7312A strain except for VP WT and SOS 6R. 
Systematic analysis of each SOSVP and non-SOSVP version of trimers using SEC, SDS-
PAGE, anti-His6 Western blotting, SEC-MALS with protein-conjugate analysis (to 
resolve glycosylation), and negative-stain EM could yield a wealth of information about 
the contribution of each modification to wild-type as well as synergistic effects of 
combined modifications. Any trimers that look compact and homogeneous under EM 
should be co-purified in complex with binding partners (CD4 and/or Fabs) to enhance 2D 
class averaging. Genes for seven anti-HIV-2 antibody Fabs have been cloned and are 
ready for expression. As negative-stain EM is an equipment-heavy and qualitative assay 
for trimer morphology, a better method may involve directly measuring relative protein 
stabilities of different trimer proteins by modulating temperature. Optimizing the co-
transfection of cleavable constructs (all but the ones with GS linker) with different ratios 
of sFurin DNA may improve the fraction of fully cleaved, soluble trimers. As previously 
demonstrated (Guenaga et al., 2015), the use of negative selection to eliminate poorly-
formed trimers may also help with 2D class averaging. Finally, the construct design of 
trimers can be further optimized. PNAS/JVI NFL makes a 20-mer GlySer linker and has 
found longer flexible linkers to be better for their constructs.  
 
 
 
 
142
	  Materials and methods 
HIV-2 gp140 trimer constructs  
The genes for all HIV-2 SOSVP trimers were assembled using synthetic gblocks 
(Integrated DNA Technologies) via touchdown PCR and subcloned into the pTT5 vector.  
We included restriction sites for EcoRI and NotI for subcloning, the signal peptide with 
sequence MDAMKRGLCCVLLLCGAVFVSPAGA to facilitate secretion from HEK293 
cells. HEK293-6E cells were transiently transfected using PEI with DNA corresponding 
to the trimer. All non-GlySer linker constructs were co-transfected with soluble Furin in a 
SOSVP:Furin ratio of 4:1. All proteins were purified via Ni-NTA affinity purification 
followed by size-exclusion chromatography on a Superdex 200 10/300 column. One liter 
of optimized HEK293-6E cell expression yielded approximately 0.5 to 2 mg of purified 
protein.  
Negative stain electron microscopy 
Negative stain grids were prepared by applying ~10ug/ml of the purified trimer to a 
freshly glow discharged ultrathin carbon film coated 400 Cu mesh grid (Ted Pella) and 
stained with 2% Uranyl acetate. Grids were viewed under FEI Tecnai T12 electron 
microscope operating at 120kV and imaged at a maginification of 42000X. Images were 
acquired on a Gatan 2kX2k CCD camera at ~1um defocus. Particles were picked 
manually picked up, and CTF estimation and phase flipping were performed using 
EMAN2. Reference-free 2D class averages were also calculated using EMAN2.  
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